Newsroom | Medtronic | 2013 Press Releases

2013 Press Releases


201720162015201420132012
Search News Releases
 
DateTitle  
12/30/13Covidien to Present at J.P. Morgan Healthcare Conference
MANSFIELD, Mass.--(BUSINESS WIRE)--Dec. 30, 2013-- Covidien (NYSE: COV), a leading global provider of healthcare products, will present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco on January 13, 2014. Joe Almeida, Chairman, President and Chief Executive Officer, will discuss the company in a presentation scheduled to begin at 8:30 a.m. PT (11:30 a.m. ET). A live audio webcast of the presentation can be accessed at... 
 Printer Friendly Version
12/20/13HeartWare Presentation At The 32nd Annual J.P. Morgan Healthcare Conference To Be Webcast
FRAMINGHAM, Mass., Dec. 20, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the 32nd Annual J.P. Morgan Healthcare Conference at 1:30 p.m. Pacific Standard Time (4:30 p.m. EST) on Tuesday, January 14, 2014. The conference is being held January 13-16 at the Westin S... 
 Printer Friendly Version
12/19/13Covidien plc to Report First-Quarter Fiscal 2014 Results on January 24, 2014
DUBLIN--(BUSINESS WIRE)--Dec. 19, 2013-- Covidien plc (NYSE: COV) will report first-quarter fiscal 2014 results on January 24, 2014. The company will host a conference call for investors at 8:30 a.m. ET. The call can be accessed in the following ways: Via webcast at Covidien’s website: http://investor.covidien.com By telephone: For both “listen-only” participants and those participants who wish to take part in... 
 Printer Friendly Version
12/17/13Medtronic Randomizes First Patients in SYMPLICITY HTN-4, the First U.S. Renal Denervation Clinical Study for Patients with Moderate Uncontrolled Hypertension
Medtronic's Second Randomized, Controlled Renal Denervation Clinical Trial in the U.S. Will Potentially Expand Access to the Symplicity(TM) Renal Denervation System for Even Larger Uncontrolled Hypertension Patient Population MINNEAPOLIS - December 17, 2013 - Medtronic, Inc. (NYSE: MDT), announced today that the first patients were randomized in SYMPLICITY HTN-4, evaluating the Symplicity(TM) renal denervation system in patients with moderate uncontrolled hypertension (systolic blood pressure g... 
Download PDFPrinter Friendly Version
12/16/13Covidien Announces Reporting Changes and Revised Revenue Guidance
DUBLIN--(BUSINESS WIRE)--Dec. 16, 2013-- Covidien plc (NYSE:COV) today provided further details regarding its previously disclosed realignment of reportable segments and announced additional changes in its revenue reporting format. These changes are designed to further align with the company’s recent reorganization and provide additional transparency of financial performance. The new format provides a worldwide view of sales across three m... 
 Printer Friendly Version
12/09/13Medtronic Announces First Human Implant of World's Smallest, Minimally Invasive Cardiac Pacemaker
Medtronic Initiates Global Clinical Trial for Miniature Transcatheter Pacemaker System MINNEAPOLIS - December 9, 2013 - Continuing its leadership in advanced pacing technology and device miniaturization, Medtronic, Inc. (NYSE: MDT), today announced the first-in-human implant of the world's smallest pacemaker: the Micra(TM) Transcatheter Pacing System (TPS). The device was implanted in a patient in Linz, Austria as part of the Medtronic global pivotal clinical trial. The Micra TPS is an investig... 
Download PDFPrinter Friendly Version
12/08/13Covidien Announces Definitive Agreement to Acquire Given Imaging
Advances Covidien strategy to more comprehensively address key specialties and procedures globally Adds Given Imaging’s broad suite of minimally invasive gastrointestinal diagnostic and monitoring solutions Accelerates development of world-class gastrointestinal portfolio focused on serving patient from diagnosis to treatment Accretive to earnings per share beginning in fiscal 2015 ... 
 Printer Friendly Version
12/06/13HeartWare Presentation At The Oppenheimer 24th Annual Healthcare Conference To Be Webcast
FRAMINGHAM, Mass., Dec. 6, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Oppenheimer 24th Annual Healthcare Conference at 7:45 a.m. ET on Wednesday, December 11, 2013.  The conference is being held December 10-11, 2013 at The Crowne Plaza Hotel in New York Cit... 
 Printer Friendly Version
12/06/13Medtronic Presents First-of-Its-Kind Data Showing Sustained Results with Cervical Disc Replacement After Seven Years
Study Shows Prestige® Cervical Disc Replacement Maintained Clinical Improvements, Lower Rate of Additional Surgical Procedures Compared to ACDF MEMPHIS, TENN. - Dec. 6, 2013 - Medtronic, Inc. (NYSE: MDT) presented 7-year clinical and radiographic outcomes of artificial disc replacement with PRESTIGE® Cervical Disc compared to anterior cervical discectomy and fusion (ACDF) yesterday at the Cervical Spine Research Society Annual Meeting held in Los Angeles, CA.  "In the past several years,... 
Download PDFPrinter Friendly Version
12/05/13Medtronic Announces Cash Dividend for Third Quarter of Fiscal Year 2014
MINNEAPOLIS - December 5, 2013 - The board of directors of Medtronic, Inc. (NYSE:MDT) today approved a cash dividend of $0.28 per share of the Company's common stock. The dividend is payable on January 24, 2014, to shareholders of record at the close of business on January 3, 2014. About MedtronicMedtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health and extending life for millions of people around the w... 
Download PDFPrinter Friendly Version
12/05/13First U.S. Implants of New Medtronic Deep Brain Stimulation System Advance Ground-Breaking Research Into Brain Activity While Therapy Is Delivered
Activa® PC+S Deep Brain Stimulation System Enables Research Toward Personalized Treatment of Neurological and Psychological Diseases MINNEAPOLIS - December 5, 2013 - Medtronic, Inc. (NYSE: MDT) today announced the first U.S. implants of a novel deep brain stimulation (DBS) system in research that may one day transform the treatment of devastating neurological and psychological disorders, such as Parkinson's disease, essential tremor, dystonia, and treatment-resistant obsessive-compulsive disord... 
Download PDFPrinter Friendly Version
12/05/13Medtronic Announces CE Mark and TGA Listing for the Symplicity Spyral(TM) Multi-Electrode Catheter and Symplicity G3(TM) Generator
Multi-Electrode System Built Upon Clinical Success and Strong Safety Profile of Single-Electrode Symplicity(TM) Renal Denervation System MINNEAPOLIS -- December 5, 2013 -- Medtronic, Inc. (NYSE: MDT), announced today CE Mark (Conformité Européenne) in Europe and Therapeutic Goods Administration (TGA) listing in Australia for its highly flexible 4 Fr multi-electrode Symplicity Spyral(TM) catheter and Symplicity G3(TM) radio frequency (RF) generator.  This new system is designed to significantly ... 
Download PDFPrinter Friendly Version
12/04/13Medtronic CFO Gary Ellis to Speak at Oppenheimer Healthcare Conference
MINNEAPOLIS - Dec 4, 2013 - Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the Oppenheimer 24th Annual Healthcare Conference on Tuesday, December 10, 2013, in New York City. Gary Ellis, senior vice president and chief financial officer of Medtronic, will make a presentation about Medtronic beginning at 9:45 a.m. EST (8:45 a.m. CST). A live audio webcast of the presentation will be available on December 10, 2013, by clicking ... 
Download PDFPrinter Friendly Version
12/04/13Medtronic Issues $500,000 in Health Access Grants to Support Diabetes Services for the Underserved of Greater Los Angeles
NORTHRIDGE, CA - December 4, 2013 - The Diabetes business of Medtronic, Inc. (NYSE: MDT) today announced that eight community organizations will receive two-year Health Access Grants from Medtronic Philanthropy, totaling $500,000, in recognition of their continued commitment to improve access to Los Angeles-area healthcare services for underserved populations, with an emphasis on diabetes. Health Access Grants are awarded in 34 communities around the world where Medtronic has a major presence. ... 
Download PDFPrinter Friendly Version
12/02/13Medtronic Surgical Technologies Opens New Customer Education and Training Center
Jacksonville Facility Will Train Surgical Teams From Around the World JACKSONVILLE, FL - December 2, 2013 - Medtronic Surgical Technologies, a division of Medtronic, Inc. (NYSE: MDT), the world's largest medical device company, will hold a ceremony to commemorate the opening of the Dr. Glen Nelson Surgeon Education and Training Center, located at the division's Jacksonville headquarters. The event will take place today at 4:30 p.m. at 6743 Southpoint Drive North. The $14 million facility conta... 
 Printer Friendly Version
12/01/13HeartWare® International Announces Acquisition Of CircuLite®, Inc.
- Acquisition expands HeartWare's technology platform into partial support for less sick patients - - Investor Conference Call on Monday, December 2, 2013 at 8:00 a.m. U.S. EST - FRAMINGHAM, Mass. and TEANECK, N.J., Dec. 1, 2013 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that it has acquired Ci... 
 Printer Friendly Version
11/26/13Medtronic EVP & President Mike Coyle to Speak at Piper Jaffray Healthcare Conference
MINNEAPOLIS - Nov 26, 2013 - Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the Piper Jaffray Healthcare Conference on Tuesday, December 3, 2013 in New York. Mike Coyle, executive vice president and president of Medtronic's Cardiac and Vascular Group will make a presentation about Medtronic beginning at 1:30 p.m. EST (12:30 p.m. CST). A live audio webcast of the presentation will be available on December 3, 2013 by clicking ... 
Download PDFPrinter Friendly Version
11/25/13HeartWare Presentation At The 25th Annual Piper Jaffray Healthcare Conference To Be Webcast
FRAMINGHAM, Mass., Nov. 25, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the 25th Annual Piper Jaffray Healthcare Conference at 2:00 p.m. ET on Tuesday, December 3, 2013.  The conference is being held December 3-4 at the Palace Hotel in New York City. A live w... 
 Printer Friendly Version
11/25/13Endurant II AAA Stent Graft from Medtronic Delivers Durable, Consistent and Proven Outcomes in Real-World Setting
Presented at VEITH, Three-Year Clinical Data from Global ENGAGE Registry Supports Innovative Device's Market-Leading Position Worldwide MINNEAPOLIS -- Nov. 25, 2013 -- Chosen for nearly one out of every two endovascular abdominal aortic aneurysm (AAA) repairs worldwide, the Endurant II AAA stent graft system from Medtronic, Inc. (NYSE: MDT) continues to demonstrate long-term durability and consistent outcomes at three years in a real-world setting. The latest data on the market-leading stent... 
Download PDFPrinter Friendly Version
11/20/13Valiant 'Mona LSA' Stent Graft System from Medtronic Demonstrates Proof of Concept in Early Feasibility Study
Presented at VEITH, Acute Results from Initial Trial of New Medical Technology Show Promise for Endovascular Approach to Thoracic Aortic Aneurysms Involving Left Subclavian Artery NEW YORK -- Nov. 20, 2013 -- The first device of its kind to undergo clinical evaluation in the United States, the Valiant "Mona LSA" branch thoracic stent graft system from Medtronic, Inc. (NYSE: MDT) has demonstrated proof of concept in a first-in-human study being conducted under the U.S. Food and Drug Adm... 
Download PDFPrinter Friendly Version
11/19/13Medtronic Reports Second Quarter Earnings
Revenue of $4.2 Billion Grew 3.3% on a Constant Currency Basis; 2.4% as Reported Non-GAAP Diluted EPS of $0.91; GAAP Diluted EPS of $0.89 Free Cash Flow of $0.9 Billion; GAAP Cash Flow from Operations of $1.0 Billion MINNEAPOLIS - Nov. 19, 2013 - Medtronic, Inc. (NYSE: MDT) today announced financial results for its second quarter of fiscal year 2014, which ended October 25, 2013. The Company reported worldwide second quarter revenue of $4.194 billion, compared to the $4.095 billion repor... 
Download PDFPrinter Friendly Version
11/18/13Late Breaking Clinical Trial Results Show Significant Delay in Atrial Fibrillation Disease Progression with Medtronic-Exclusive Pacing Features
MINERVA Trial at AHA Meeting Shows Medtronic Pacemakers Reduce the Progression of Permanent AF by 61 Percent MINNEAPOLIS and DALLAS - Nov.18, 2013 - New research shows that Medtronic, Inc. (NYSE: MDT) pacemakers with enhanced pacing features have the ability to slow the progression of atrial fibrillation (AF) in patients with bradycardia, or a slow heartbeat. Presented as a late breaking clinical trial at the American Heart Association's Scientific Sessions 2013, the MINERVA (MINimizE Right V... 
Download PDFPrinter Friendly Version
11/15/13FDA Classifies Medtronic's Worldwide Voluntary Field Action on Guidewires as Class I Recall
MINNEAPOLIS -- Nov. 15, 2013 -- Medtronic, Inc. (NYSE: MDT) announced today that the U.S. Food and Drug Administration (FDA) has classified the company's recently initiated voluntary field action related to certain guidewires as a Class I recall. Based on an internal investigation following a limited number of complaints, including one patient injury, Medtronic began notifying hospitals and distributors worldwide the week of Oct. 21 that some models of its guidewires from recent lots have the ... 
Download PDFPrinter Friendly Version
11/14/13Medtronic to Resume Sales of CoreValve System in Germany
MINNEAPOLIS - Nov. 14, 2013 - Medtronic, Inc. (NYSE: MDT) announced that a German court today ordered the discontinuation, in its entirety, of a prior court ruling that prohibited Medtronic from commercially marketing or selling the CoreValve® System in Germany since August 26, 2013. "Medtronic is very pleased with this decision as it will ensure that patients in Germany who need aortic valve replacement will have access to this life-saving therapy," said John Liddicoat, M.D., senior ... 
Download PDFPrinter Friendly Version
11/14/13Covidien to Present at Jefferies 2013 Global Healthcare Conference
MANSFIELD, Mass.--(BUSINESS WIRE)--Nov. 14, 2013-- Covidien (NYSE: COV), a leading global provider of healthcare products, will present at the Jefferies 2013 Global Healthcare Conference in London on November 21, 2013. Coleman N. Lannum, Vice President, Investor Relations, will discuss the Company in a presentation scheduled to begin at 10:00AM local time (5:00AM ET). A live audio webcast of the presentation can be accessed at Covidien’s ... 
 Printer Friendly Version
11/13/13Medtronic Responds to Super Typhoon Haiyan Relief Efforts
MINNEAPOLIS - Nov. 13, - 2013 - Medtronic announced today a grant of $100,000 to the Philippines Red Cross to support relief efforts in the areas affected by the Super Typhoon Haiyan on November 8. Medtronic employees wishing to assist directly with local recovery efforts are allowed five days of paid leave in order to serve as needed.  Additionally, employee donations to qualified disaster relief organizations will be doubled through Medtronic's Matching Grants program.  About MedtronicMedtr... 
 Printer Friendly Version
11/11/13Covidien Launches Response Effort in Support of Areas Impacted by Typhoon in the Philippines
Company to provide $50,000 in cash and product donations to aid in relief efforts MANSFIELD, Mass.--(BUSINESS WIRE)--Nov. 11, 2013-- Covidien (NYSE: COV), a leading global supplier of healthcare products, today announced it would donate $50,000 in support of relief efforts in communities devastated by Typhoon Haiyan in the Philippines. All of its employees in the Philippines are safe, and its offices in Manila are undamaged and operatio... 
 Printer Friendly Version
11/11/13Medtronic to Announce Financial Results for Its Second Quarter of Fiscal Year 2014
MINNEAPOLIS - Nov. 11, 2013 - Medtronic, Inc. (NYSE: MDT) announced today it will report financial results for the second quarter of its fiscal year 2014 on Tuesday, November 19, 2013. A news release will be issued at approximately 6:15 a.m. CST and will be available at http://newsroom.medtronic.com. The earnings news release will include summary financial information for Medtronic's second quarter, which ended October 25, 2013. Medtronic will host a webcast at 7 a.m. CST to discuss financial r... 
Download PDFPrinter Friendly Version
11/08/13HeartWare Presentation At The Canaccord Genuity Medical Technology & Diagnostics Forum To Be Webcast
FRAMINGHAM, Mass., Nov. 8, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Canaccord Genuity Medical Technology & Diagnostics Forum at 1:30 p.m. ET on Thursday, November 14, 2013.  The one-day conference is being held at the Westin Grand Central in New York... 
 Printer Friendly Version
11/08/13Covidien Reports Fourth-Quarter and Fiscal 2013 Results
Net sales up 2% (up 5%, excluding foreign exchange rate movement); Medical Devices sales up 3% (up 6%, excluding foreign exchange rate movement) Fourth-quarter diluted GAAP earnings per share from continuing operations were $0.79; excluding specified items, adjusted diluted earnings per share from continuing operations were $0.91 Fiscal 2013 diluted GAAP earnings per share from continuing operations we... 
Download PDFPrinter Friendly Version
11/07/13FDA Approves Medtronic-Proprietary Software for Use with Non-Medtronic Leads to Detect Defibrillator Lead Issues
LIA Software Proven to Detect Lead Failures More Frequently Than Impedance Alone on Riata, Durata and Endotak Leads MINNEAPOLIS - Nov. 7, 2013 - Medtronic, Inc. (NYSE:MDT) today announced FDA approval of its Lead Integrity Alert (LIA) software for use with non-Medtronic leads. Proprietary and exclusive software that resides in Medtronic defibrillators, LIA is now approved to report performance issues on Durata® and Riata® defibrillator leads (St. Jude Medical) and Endotak® (Boston Scientific) d... 
Download PDFPrinter Friendly Version
11/07/13HeartWare International Reports $54.8 Million In Third Quarter 2013 Revenue; 140% Increase From Third Quarter Of 2012
- Strong continued adoption of HeartWare® System within U.S. commercial launch results in domestic revenue of $28.2 million, up 12% sequentially from Second Quarter of 2013; - International Revenue of $26.6 million, up 38% from Third Quarter of 2012; Bolstered by European Market Strength FRAMINGHAM, Mass., Nov. 7, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing ... 
 Printer Friendly Version
11/05/13HeartWare Presentation At The Credit Suisse Healthcare Conference To Be Webcast
FRAMINGHAM, Mass., Nov. 5, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Credit Suisse Healthcare Conference on Tuesday, November 12, 2013 at 10:30 a.m. MST. The conference will be held November 11-14 at the Phoenician Hotel in Scottsdale, Arizona. A live w... 
 Printer Friendly Version
11/05/13Medtronic Announces FDA Approval to Enroll First U.S. Renal Denervation Clinical Study for Patients with Moderate Uncontrolled Hypertension
SYMPLICITY HTN-4 Will Potentially Expand Access for Additional Patients at Risk for Cardiovascular Complications Related to Uncontrolled Hypertension MINNEAPOLIS -- November 5, 2013 -- Medtronic, Inc. (NYSE: MDT), announced today that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) allowing the company to initiate SYMPLICITY HTN-4, the first randomized trial to investigate renal denervation for the treatment of moderate uncontrolled hypertensio... 
Download PDFPrinter Friendly Version
11/01/13Medtronic, Lilly Diabetes Join Together as First Ever National Presenting Sponsors of the JDRF Walk To Cure Diabetes
Alliance showcases shared commitment to type 1 diabetes community; kicks off activities for T1Day observance Nov. 1    News Highlights Medtronic and Lilly Diabetes become first ever national presenting sponsors of the #JDRF Walk to Cure #Diabetes Medtronic, Lilly Diabetes help fund more than $500K for #T1D research through #JDRF Walk to Cure #Diabetes national sponsorship Medtronic, Lilly Diabetes' #JDRF Walk to Cure #Diabetes national sponsorship announcement kicks off #T1Day and #NDAM ... 
Download PDFPrinter Friendly Version
10/31/13In Trial of Rivals, Medtronic's Resolute Integrity Stent Outperforms Promus Element Stent on Longitudinal Strength
Presented at TCT and Published by The Lancet, Results of DUTCH PEERS Negate Notion of Class Effect with Structural Stability of 'More Flexible and Highly Deliverable Devices' SAN FRANCISCO -- Oct. 31, 2013 -- In the first head-to-head randomized controlled trial of "third-generation" durable-polymer drug-eluting stents for the treatment of coronary artery disease in an "all-comers" patient population, the Resolute Integrity drug-eluting stent (DES) from Medtronic, Inc. (NYSE... 
Download PDFPrinter Friendly Version
10/31/13In Studies of Medtronic Stents, Patients Who Interrupted Dual Antiplatelet Therapy Early Saw No Increased Thrombosis Risk
New Data Presented at TCT and Published by JAMA Affirms Excellent Safety Profile of Zotarolimus-Eluting Stents  SAN FRANCISCO -- Oct. 31, 2013 -- According to findings from several studies presented at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, patients with coronary artery disease who received an Endeavor or Resolute drug-eluting stent from Medtronic, Inc. (NYSE: MDT) and subsequently interrupted their dual antiplatelet therapy (DAPT) earlier than cu... 
Download PDFPrinter Friendly Version
10/31/13EPFL to Create "Medtronic Chair in Neuro-Engineering"
Medtronic Sponsors Research and Education Within EPFL's Campus Biotech Project in Geneva LAUSANNE/TOLOCHENAZ -- October 31, 2013 -- The Ecole Polytechnique Fédérale Lausanne (EPFL) and global medical technology leader Medtronic have signed a sponsorship agreement to create an EPFL chair in Neuro-Engineering. This chair will be located in Geneva's Campus Biotech, next to the research teams of the Human Brain Project, EPFL's Center for Neuroprosthetics (CNP) and the new Wyss institute for bio- an... 
Download PDFPrinter Friendly Version
10/31/13Statement from Medtronic Coinciding with Participation in the 8th Investment Advisory Council of Turkey
ISTANBUL- 31 October 2013 - Medtronic today issued the following statement from the 8th Investment Advisory Council (IAC) of Turkey.  The meeting gathered representatives of leading international institutions such as the World Bank, prominent multinational and Turkish companies, as well Cabinet Members to exchange ideas between international business leaders and level policy makers to strengthen the investment climate of Turkey. Since its inauguration in 2004, Prime Minister, HE Erdogan has ch... 
 Printer Friendly Version
10/30/13Medtronic CoreValve U.S. Pivotal Trial Affirms Benefits of Self-Expanding Transcatheter Aortic Valve Replacement in Patients Treated Via Alternative Access Routes
First Rigorous Prospective Analysis of Extreme Risk Patients Presented at TCT13 SAN FRANCISCO and MINNEAPOLIS - Oct. 30, 2013 - Following the first U.S. data presented on the Medtronic CoreValve® System in patients treated via the transfemoral approach, Medtronic, Inc. (NYSE: MDT) today announced the positive results of patients treated via alternative access routes as part of the same Extreme Risk Study within the CoreValve U.S. Pivotal Trial. Presented at Transcatheter Cardiovascular Therapeu... 
Download PDFPrinter Friendly Version
10/30/13Medtronic Presents Three-Year Results From SYMPLICITY HTN-2 Showing Significant and Sustained Drops in Blood Pressure After Treatment with the Symplicity(TM) Renal Denervation System
Longest-term data from the first randomized, controlled trial of renal denervation presented at the 25th Annual Transcatheter Cardiovascular Therapeutics (TCT) Symposium MINNEAPOLIS and SAN FRANCISCO - October 30, 2013 - Medtronic, Inc. (NYSE: MDT) presented three-year data from SYMPLICITY HTN-2, the first and longest-running randomized, controlled clinical trial of renal denervation, which continue to demonstrate results consistent with data reported previously at six, 12 and 24-months of foll... 
Download PDFPrinter Friendly Version
10/29/13Medtronic Statement On European Patent Office Preliminary Opinion
Medtronic, Inc. (NYSE: MDT) today provided the following statement: As part of a patent opposition proceeding, the European Patent Office (EPO) today issued a preliminary opinion on the validity of Edwards’ EP2055266 Spenser patent, which was the basis for the Aug. 26, 2013, injunction prohibiting further sales of CoreValve® System in Germany. The preliminary opinion says the patent claims are not valid because of an invalid priority claim and because claims are impermissibly broader th... 
 Printer Friendly Version
10/29/13Medtronic CoreValve U.S. Pivotal Trial Results Reveal Positive Outcomes for Patients
Trial Finds Lifesaving Technology Successfully Meets Primary and Secondary Endpoints FDA  Determines Expert Panel Not Required for Extreme Risk FDA Will Evaluate Extreme Risk Patients Separately from High Risk Patients SAN FRANCISCO and MINNEAPOLIS - Oct. 29, 2013 - Medtronic, Inc. (NYSE: MDT) today announced the highly anticipated results from the CoreValve U.S. Pivotal Trial, the first U.S. data presented on the Medtronic CoreValve® System. The study of the novel self-expanding de... 
Download PDFPrinter Friendly Version
10/28/13Covidien to Sell Confluent Surgical Product Line to Integra LifeSciences
DUBLIN--(BUSINESS WIRE)--Oct. 28, 2013-- Covidien (NYSE: COV), a leading global provider of healthcare products, announced today that it has entered into a definitive agreement with Integra LifeSciences Corporation to sell its Confluent Surgical product line. The transaction is expected to close by March 31, 2014, subject to receipt of regulatory approvals. Under the terms of the agreement, Covidien will receive an initial cash paym... 
 Printer Friendly Version
10/25/13HeartWare Schedules Third Quarter Conference Call And Webcast
FRAMINGHAM, Mass., Oct. 25, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ:HTWR) has scheduled a conference call to discuss its financial results for the three months ended September 30, 2013, at 8:00 a.m. U.S. Eastern Standard Time on Thursday, November 7, 2013.  The Company plans to release the financial results prior to the conference call. The conference call with management will discuss the Company's financial results, highlights from the third quarter and business outlook.  ... 
 Printer Friendly Version
10/22/13Medtronic Initiates Clinical Study of Recapturable CoreValve Evolut R
First Patients Successfully Treated With Novel 'CoreValve Evolut R' Transcatheter Valve MINNEAPOLIS - Oct. 22, 2013 - Medtronic, Inc. (NYSE: MDT) today announced the first implants in the CoreValve Evolut R Clinical Study, which will evaluate  the safety and effectiveness of the new Medtronic CoreValve® Evolut(TM) R Recapturable System. This recapture-enabled valve and delivery system offers new capabilities that are designed to advance deliverability and valve performance while providing the o... 
Download PDFPrinter Friendly Version
10/21/13Medtronic First to Offer Lateral Access Procedures to All Levels of the Lower Lumbar Spine
MEMPHIS, Tenn. - Oct. 21, 2013 - Medtronic, Inc. (NYSE: MDT) the world leader in spinal technology, announced today the launch of the first procedure that allows lateral access to the most common operative level of the spine at the annual meeting of the Congress of Neurological Surgeons in San Francisco, CA. OLIF51TM Procedure is an innovative procedural solution that enables reproducible lateral access to the L5-S1 disc space.  "For the first time, along with the OLIF25TM Procedure, the s... 
Download PDFPrinter Friendly Version
10/21/13Medtronic Launches New Device To Remove Coronary Thrombus
Long-Time Market Leader Introduces U.S. Cardiologists to Greater Power and Superior Deliverability of Next-Generation 'Export Advance' Aspiration Catheter MINNEAPOLIS -- Oct. 21, 2013 -- With more than a decade of market leadership in medical devices designed to remove thrombus from coronary arteries, Medtronic, Inc. (NYSE: MDT) announced today the U.S. launch of the Export Advance aspiration catheter, which offers greater power and superior deliverability.  Recently cleared by the U.S. Food ... 
Download PDFPrinter Friendly Version
10/19/13Medtronic Statement on Medical Device Security
Medtronic takes device security and any threat to patient safety seriously. Medtronic is actively engaged with security research firms and regularly conducts and uses independent assessments to improve the security of our systems. We continuously monitor the security of our devices and if new vulnerabilities are revealed, Medtronic will assess whether additional security measures can be implemented without compromising the therapy that the device is designed to deliver to patients. The security... 
Download PDFPrinter Friendly Version
10/17/13Medtronic to Unveil CoreValve U.S. Pivotal Trial Results at TCT 2013
Late Breaking Clinical Trial Features the First U.S. Data of Novel Self-Expanding Transcatheter Valve at Premier Interventional Cardiology Meeting Other Late-Breakers Feature New Clinical Data on Endeavor and Resolute Drug-Eluting Stents; Three Year Results of Symplicity HTN-2 Study to be Presented MINNEAPOLIS -- Oct. 17, 2013 -- Medtronic, Inc. (NYSE: MDT) today announced its schedule of notable sessions that will be presented at the 25th Annual Transcatheter Cardiovascular Therapeutics (TCT)... 
Download PDFPrinter Friendly Version
10/14/13Covidien Releases Clinical Data Supporting Treatment and New Approach to Peripheral Arterial Disease
MANSFIELD, Mass.--(BUSINESS WIRE)--Oct. 14, 2013-- Covidien (NYSE: COV), a leading global provider of healthcare products, has released positive final results from its DURABILITY II study and promising preliminary data from its DEFINITIVE AR trial at the Vascular Interventional Advances (VIVA) 2013 conference in Las Vegas, NV. These studies demonstrate the safety and effectiveness of technologies used in the treatment of peripheral arterial diseas... 
 Printer Friendly Version
10/14/13Medtronic Announces Ten Bakken Invitation Honorees
Global Program Honors People Who Have Overcome Health Challenges with the Help of Medical Technology and Are Now Giving Back to Their Communities MINNEAPOLIS - Oct. 14, 2013 - Medtronic, Inc. (NYSE: MDT) today announced the selection of the first 10 Bakken Invitation Honorees,  people who with the help of medical technology have overcome health challenges and are now making significant contributions in their communities.    The Bakken Invitation is a global call to all peop... 
Download PDFPrinter Friendly Version
10/11/13Covidien Launches New Capnography Monitoring Solution
Capnostream® 20p bedside monitor offers enhanced features for increasing patient safety in hospitals BOULDER, Colo.--(BUSINESS WIRE)--Oct. 11, 2013-- Covidien, a leading global provider of healthcare products and recognized innovator in patient monitoring and respiratory care devices, today launched the Capnostream® 20p bedside monitor. The new capnography solution, with Covidien’s Microstream® technology, offers enhanced features that ... 
 Printer Friendly Version
10/09/13Covidien Launches Two Enhanced LigaSure™ Vessel Sealing Products at American College of Surgeons Clinical Congress 2013
LigaSureTM portfolio celebrates 15th anniversary with redesigned LigaSure Impact™ and LigaSure™ Blunt Tip, offering improved ergonomics for a better surgical experience MANSFIELD, Mass.--(BUSINESS WIRE)--Oct. 9, 2013-- Covidien (NYSE: COV), a leading global provider of healthcare products, is strengthening its vessel sealing portfolio with the launch of two advanced energy devices, the LigaSure Impact™ curved large jaw open sealer/divid... 
 Printer Friendly Version
10/09/13Apollo Hospitals and Medtronic Announce a Collaboration to Bring an Affordable, Portable Hemodialysis System to India
New Hemodialysis Platform Would Enable Delivery of Life-Saving Therapy From the Hospital to the Home NEW DELHI - October 9th, 2013 - Apollo Hospitals Enterprise Ltd., one of the leading healthcare providers in Asia, and Medtronic, Inc. (NYSE: MDT), the global leader in medical technology, today announced a collaboration to bring to market an innovative, affordable and portable hemodialysis system in India to help improve access to care for End Stage Renal Disease (ESRD) patients who need Renal... 
Download PDFPrinter Friendly Version
10/08/13FDA Advisory Panel Recommends Expanded Indication for Medtronic CRT Devices in Patients with AV Block and Reduced Heart Function
Panel Vote Underscores Clinical Benefits of Biventricular Pacing for Better Patient Outcomes and Improved Quality of Life MINNEAPOLIS - Oct. 8, 2013 - The U.S. Food and Drug Administration's (FDA) Circulatory Systems Devices Advisory Panel today voted that biventricular (BiV) pacing with Medtronic, Inc. (NYSE: MDT) devices is beneficial for treating patients who have atrioventricular (AV) block and left ventricular (LV) systolic dysfunction, compared to conventional right ventricular pacing. Th... 
 Printer Friendly Version
10/03/13Medtronic Announces CE Mark and European Launch of Compact CORNERSTONE-SR® Alliance(TM), A New Cervical Cage
New Cage Compatible with Existing Compact CORNERSTONE-SR® Instrumentation Complete, Condensed Set Size Takes Less Space and More Intuitive for Operating Room Staff MEMPHIS, Tenn. - October 3rd, 2013 - Medtronic, Inc. (NYSE:  MDT) the world leader in spinal technology, announced today the CE Mark (Conformité Européenne) and the European launch of a new cervical cage system which expands the successful Compact CORNERSTONE-SR® platform of cages.   The Compact CORNERSTONE-SR® Alliance(TM) cage is ... 
Download PDFPrinter Friendly Version
09/30/13Covidien plc to Report Fourth-Quarter Results on November 8, 2013
DUBLIN--(BUSINESS WIRE)--Sep. 30, 2013-- Covidien plc (NYSE: COV) will report fourth-quarter results on November 8, 2013, before trading begins. The Company will hold a conference call for investors at 8:30 a.m. ET. The call can be accessed in the following ways: At Covidien’s website: http://investor.covidien.com By telephone: For both “listen-only” participants and those participants who wish to take ... 
 Printer Friendly Version
09/27/13Medtronic Gains Approval of First Artificial Pancreas Device System with Threshold Suspend Automation
MiniMed® 530G with Enlite® Automatically Stops Insulin Delivery If Sensor Glucose Levels Fall Below a Predetermined Threshold MINNEAPOLIS - September 27, 2013 -Medtronic, Inc. (NYSE:MDT) today announced the U.S. Food and Drug Administration (FDA) approval of the MiniMed® 530G with Enlite®, a breakthrough, first-generation artificial pancreas system with Threshold Suspend automation for people with diabetes.  Medtronic's system is the first in the United States that can automatically stop i... 
Download PDFPrinter Friendly Version
09/24/13FDA Approves Medtronic's Complete 'SE' Vascular Stent for Use in Superficial Femoral and Proximal Popliteal (Leg) Arteries
New Indications for Self-Expanding Device Address Broad Area of Peripheral Artery Disease MINNEAPOLIS -- September 24, 2013 -- Expanding its role in the treatment of peripheral artery disease in the United States, Medtronic, Inc. (NYSE: MDT) announced today that the U.S. Food and Drug Administration (FDA) has approved the Complete SE (self-expanding) vascular stent for use in the lower extremities -- specifically, the superficial femoral artery (SFA) and proximal popliteal artery (PPA), which c... 
Download PDFPrinter Friendly Version
09/23/13Late Breaking Clinical Trial Reveals Reduced Risk of Atrial Fibrillation for Patients with Medtronic Devices Featuring AdaptivCRT
Long-Term Clinical Trial Results Further Emphasize Safety and Added Benefits of Medtronic Proprietary Feature MINNEAPOLIS and ORLANDO - Sept. 23, 2013 - Medtronic, Inc. (NYSE: MDT) today announced clinical trial results showing that heart failure patients treated with its exclusive AdaptivCRT® feature experienced a nearly 50 percent reduction in atrial fibrillation (AF) risk. Pioneered by Medtronic, the AdaptivCRT technology is a feature on certain cardiac resynchronization therapy-defibrillat... 
Download PDFPrinter Friendly Version
09/20/13Covidien Launches Response Effort in Support of Colorado Flood Relief
Provides $50,000 and in-kind donations to aid in relief efforts MANSFIELD, Mass.--(BUSINESS WIRE)--Sep. 20, 2013-- Covidien (NYSE: COV), a leading global supplier of healthcare products, donated $50,000 in support of relief efforts in flood-damaged communities in Colorado. All of its 1,850 employees in Colorado are safe and its offices in Boulder are undamaged and operational. Covidien is working closely with local and national disaste... 
 Printer Friendly Version
09/19/13Covidien Announces Dividend Increase
DUBLIN--(BUSINESS WIRE)--Sep. 19, 2013-- Covidien plc (NYSE: COV) today announced that its Board of Directors has declared a 23% increase in the quarterly dividend rate, from $0.26 per ordinary share to $0.32 per ordinary share. “This increase reflects our good performance to date in 2013 and our confidence in further growth,” said José (Joe) E. Almeida, Chairman, President and CEO. “We remain committed to using our strong cash flow to ... 
 Printer Friendly Version
09/18/13Medtronic Responds to Flooding in Colorado
MINNEAPOLIS - September 18, 2013 - Medtronic, Inc. (NYSE: MDT) announced today that it has pledged $25,000 through Medtronic Philanthropy to support flooding relief efforts in Larimer and Boulder Counties, Colorado. The $25,000 will be directed to the Colorado American Red Cross to provide basic needs for displaced residents and to support recovery efforts. Medtronic employees in the affected area also are being offered paid leave to volunteer assisting with relief efforts, and the company wil... 
Download PDFPrinter Friendly Version
09/17/13Medtronic Opens New Customer Innovation Centre in Galway, Ireland
Centre Will Facilitate Collaboration Between Physicians and Engineers to Develop New Innovations in Medical Technology MINNEAPOLIS AND GALWAY - September 17, 2013 - Medtronic, Inc. (NYSE: MDT) today opened a new Customer Innovation Centre in Galway, Ireland, providing state of the art facilities for physicians and Medtronic engineers to work together on developing new therapies that will improve clinical outcomes, provide economic value and increase access to quality healthcare for patients aro... 
Download PDFPrinter Friendly Version
09/12/13Covidien Announces Highlights from Investor Meeting
NEW YORK--(BUSINESS WIRE)--Sep. 12, 2013-- Covidien (NYSE: COV), a leading global provider of healthcare products, today outlined the key strategic initiatives, growth opportunities and innovations that are expected to drive the Company’s growth in 2014 and beyond at a meeting held here for the investment community. Chairman, President and CEO José (Joe) E. Almeida spoke about Covidien’s plans to address the changing healthcare landscape a... 
 Printer Friendly Version
09/12/13Medtronic Named One of the World's Leading Companies for Sustainability
MINNEAPOLIS - Sept. 12, 2013 - Medtronic, Inc. (NYSE: MDT) is one of the world's leading companies for sustainability, according to new ratings released today. For the third year in a row, Medtronic was named to the Dow Jones Sustainability World Index (DJSI World), which analyzes companies on a variety of sustainability criteria, including economic performance, environmental stewardship and social responsibility. This adds to the recognition Medtronic received earlier this year from FTSE4Good. ... 
Download PDFPrinter Friendly Version
09/06/13Medtronic CFO Gary Ellis to Speak at Morgan Stanley Healthcare Conference
MINNEAPOLIS - Sep 6, 2013 - Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the Morgan Stanley 2013 Global Healthcare Conference on Tuesday, September 10, 2013, in New York. Gary Ellis, senior vice president and chief financial officer of Medtronic, will make a presentation about Medtronic beginning at 9:10 a.m. EDT (8:10 a.m. CDT). A live audio webcast of the presentation will be available on September 10, 2013, by clicking ... 
Download PDFPrinter Friendly Version
09/04/13Covidien Announces Investor Meeting Agenda
DUBLIN--(BUSINESS WIRE)--Sep. 4, 2013-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced the agenda for its investor meeting on Thursday, September 12, 2013. The event will be held at Cipriani, 55 Wall Street, New York, NY. A webcast of the presentations will begin at approximately 2:20 pm ET and will conclude by 5:00 pm ET. The program will begin with rotational sessions where attendees will v... 
 Printer Friendly Version
09/03/13Medtronic Presents Final Three-Year Data From Symplicity HTN-1 Showing Significant and Sustained Drops in Blood Pressure After Treatment with the Symplicity(TM) Renal Denervation System
Final Clinical Outcomes from First and Longest-Running Renal Denervation Clinical Study Presented During European Society of Cardiology Congress and Accepted for Publication in The Lancet MINNEAPOLIS AND AMSTERDAM -- September 3, 2013 -- Medtronic, Inc. (NYSE: MDT), announced today at the European Society of Cardiology (ESC) Congress the final three-year results from Symplicity HTN-1, the first and longest running clinical study investigating the safety and efficacy of renal denervation, which ... 
Download PDFPrinter Friendly Version
09/02/13Medtronic Reports Strong Safety and Sustained Clinical Efficacy Results of the Symplicity(TM) Renal Denervation System from the Global SYMPLICITY Registry
Six and 12-Month Data from Largest Real-World Patient PopulationConsistent with Symplicity Randomized Clinical Trial MINNEAPOLIS and AMSTERDAM - September 2, 2013 - Medtronic, Inc. (NYSE: MDT), announced today at the European Society of Cardiology (ESC) Congress, new data from the Global SYMPLICITY Registry that continue to affirm the strong safety profile of the Symplicity(TM) renal denervation system in a real-world patient population. Among the 1,158 patients analyzed in the registry with... 
Download PDFPrinter Friendly Version
09/02/13Medtronic Announces Formation of Hospital Solutions Business Aimed at Driving Efficiencies and Cost Savings
Medtronic Hospital Solutions Signs First Contracts with Two Leading Hospitals in Europe and Makes Equity Investment in NGC Medical MINNEAPOLIS AND TOLOCHENAZ - September 2, 2013 - Medtronic, Inc. (NYSE: MDT) today announced the formation of Medtronic Hospital Solutions, a new business focused on developing novel partnerships with hospitals to provide services directly related to hospital operational efficiency.  The new business will focus initially on offering services in Europe to manage and... 
Download PDFPrinter Friendly Version
08/29/13Covidien Prevails in Patent Action Against Applied Medical Resources
NEW HAVEN, Conn.--(BUSINESS WIRE)--Aug. 29, 2013-- Covidien (NYSE: COV), a global healthcare products company, announced that it has prevailed against Applied Medical Resources, Inc. in a patent action before the United States Court of Appeals for the Federal Circuit. In May 2011, Applied Medical sued Covidien in connection with Covidien’s sale of certain trocar products. On August 27, the United States Court of Appeals for the Federal Circuit affirmed the lower court’s previous ruling that Co... 
 Printer Friendly Version
08/29/13Medtronic To Set Up Global Center Of Excellence In Singapore For Business Model Innovation
MINNEAPOLIS and SINGAPORE, Aug. 29, 2013 - Medtronic announced today the official opening of a global Center of Excellence (CoE) for Business Model Innovation in Singapore.  This new Center, based in the current local Medtronic facility, is responsible for designing, testing and scaling new business models for the rapidly growing developing markets across Asia. Next to developing new financial approaches, the center will also develop new commercial models to systematically address market growth ... 
Download PDFPrinter Friendly Version
08/27/13HeartWare Receives FDA Approval To Enroll Supplemental Patient Cohort In Destination Therapy Trial
- Amended protocol includes enhanced blood pressure monitoring to ensure optimal patient management - FRAMINGHAM, Mass. and SYDNEY, Aug. 27, 2013 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that the U.S. Food and Drug Administration (FDA) has approved an IDE (Investigational Device Exemption) Supplem... 
 Printer Friendly Version
08/27/13Covidien Opens US$21 Million Research & Development and Training & Education Center in South Korea
First of its kind center in Korea fosters medical innovation and contributes to improving patient care with the latest technologies SEOUL, South Korea--(BUSINESS WIRE)--Aug. 27, 2013-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced the opening of the Covidien Center of Innovation Korea (CCI Korea), its first research & development (R&D) and training & education center in Korea. With a tot... 
 Printer Friendly Version
08/22/13Medtronic Announces Cash Dividend for Second Quarter of Fiscal Year 2014
MINNEAPOLIS - August 22, 2013 - The board of directors of Medtronic, Inc. (NYSE:MDT) today approved a cash dividend of $0.28 per share of the company's common stock. The quarterly dividend represents a 7.7 percent increase over the prior year. The dividend is payable on October 25, 2013, to shareholders of record at the close of business on October 4, 2013. Medtronic, a constituent of the S&P 500 Dividend Aristocrat index, has committed to returning 50 percent of its free cash flow to shareholde... 
Download PDFPrinter Friendly Version
08/20/13Medtronic Reports First Quarter Earnings
Revenue of $4.1 Billion Grew 3% at Constant Currency; 2% as Reported International Revenue Grew 9% at Constant Currency; 6% as Reported Non-GAAP Diluted EPS of $0.88; GAAP Diluted EPS of $0.93 MINNEAPOLIS - August 20, 2013 - Medtronic, Inc. (NYSE: MDT) today announced financial results for its first quarter of fiscal year 2014, which ended July 26, 2013. The company reported worldwide first quarter revenue of $4.083 billion, compared to the $4.008 billion reported in the first quarter o... 
Download PDFPrinter Friendly Version
08/19/13Covidien Initiates a Voluntary Recall of Certain Lots of Monoject™ Prefill Flush Syringes Sold in the United States and Bermuda
Mansfield, MA – August 19, 2013 – Covidien today announced that it has initiated a voluntary recall of certain lots of Monoject™ prefill flush syringes. Reasons for Recall: This recall is being conducted due to the risk that a number of the syringes were filled with water but not subjected to the autoclave sterilization process. These products are labeled as either sodium chloride flush or heparin lock flush. Some of these syringes have the mismatched syringe tip cap, syringe label, filled vol... 
 Printer Friendly Version
08/15/13Medtronic Submits First 'PMA' Module for IN.PACT Admiral Drug-Eluting Balloon
Med-Tech Leader Continues to Project Pre-Market Approval from U.S. FDA for Novel Peripheral Angioplasty Device in Second Half of 2015 MINNEAPOLIS -- Aug. 15, 2013 -- Marking a major milestone in the advancement of new treatments for peripheral artery disease, Medtronic, Inc. (NYSE: MDT) today announced the submission of its first pre-market approval (PMA) module to the U.S. Food and Drug Administration (FDA) for the IN.PACT Admiral drug-eluting balloon. Designed to treat atherosclerotic lesions... 
Download PDFPrinter Friendly Version
08/14/13Medtronic to Webcast Annual Shareholder Meeting
MINNEAPOLIS - Aug. 14, 2013 - Medtronic investors and other interested parties are invited to participate in a live video webcast of the Medtronic Annual Shareholder Meeting on Thursday, August 22, 2013, at 10:30 a.m. CDT. The webcast can be accessed by clicking on the Investor section link through the Medtronic website at www.medtronic.com on Thursday, August 22, 2013. Within 24 hours of the webcast, a replay and a transcript of the prepared remarks will be available under the Events and Pres... 
Download PDFPrinter Friendly Version
08/13/13Covidien Introduces New Barrx™ RF Ablation Catheter for Treating Barrett’s Esophagus
Barrx™ Channel RFA Endoscopic Catheter eliminates need for multiple endoscope introductions; also offers enhanced visualization SUNNYVALE, Calif.--(BUSINESS WIRE)--Aug. 13, 2013-- Covidien (NYSE: COV), a leading global provider of healthcare products, announced the expansion of its portfolio of radiofrequency ablation (RFA) catheters with the launch of the Barrx™ Channel RFA Endoscopic Catheter for treating Barrett’s esophagus and certain gastrointestinal bleeding disorders1. Left untreated, B... 
 Printer Friendly Version
08/12/13Medtronic to Announce Financial Results for Its First Quarter of Fiscal Year 2014
MINNEAPOLIS - Aug 12, 2013 - Medtronic, Inc. (NYSE: MDT) announced today it will report financial results for the first quarter of its fiscal year 2014 on Tuesday, August 20, 2013. A news release will be issued at approximately 6:15 a.m. CDT and will be available at www.medtronic.com/newsroom. The earnings news release will include summary financial information for Medtronic's first quarter, which ended July 26, 2013. Medtronic will host a webcast at 7 a.m. CDT to discuss financial results for ... 
Download PDFPrinter Friendly Version
08/12/13Medtronic Advances Healthcare Services and Solutions Strategy with Acquisition of Cardiocom
Cardiocom's Patient Management Offerings Reduce Healthcare Costs and Improve Care   MINNEAPOLIS - August 12, 2013 - Medtronic, Inc. (NYSE: MDT) today announced the closing of the acquisition of Cardiocom, a privately held developer and provider of integrated telehealth and patient services for the management of chronic diseases, in an all cash transaction valued at $200 million.  Medtronic expects the net impact from this transaction to be neutral to fiscal year 2014 earnings and for this trans... 
Download PDFPrinter Friendly Version
08/09/13HeartWare Presentation At The Canaccord Genuity 2013 Annual Growth Conference To Be Webcast
FRAMINGHAM, Mass. and SYDNEY, Aug. 9, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Canaccord Genuity 2013 Annual Growth Conference at 3:00 p.m. EDT on Wednesday, August 14, 2013.  The conference is being held August 14-15 at the The InterContinent... 
 Printer Friendly Version
08/08/13HeartWare International Reports $50.8 Million In Second Quarter 2013 Revenue; 75% Increase From Second Quarter Of 2012
- U.S. Revenues of $25.1 million, up from $4.2 million in Second Quarter of 2012; Reflects Strong Initial Commercialization of HVAD® Pump in U.S. - - Conference call today at 8:00 a.m. U.S. E.T. - FRAMINGHAM, Mass. and SYDNEY, Aug. 8, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced revenue of $5... 
 Printer Friendly Version
08/07/13New Medtronic Deep Brain Stimulation System the First to Sense and Record Brain Activity While Delivering Therapy
First Implant of Activa® PC+S Deep Brain Stimulation System Initiates Research That Could One Day Significantly Change How Neurological and Psychological Diseases are Treated MINNEAPOLIS AND MUNICH - August 7, 2013 - Medtronic, Inc. (NYSE: MDT) today announced the first implant of a novel deep brain stimulation (DBS) system that, for the first time, enables the sensing and recording of select brain activity while simultaneously providing targeted DBS therapy. This initiates research on how the ... 
Download PDFPrinter Friendly Version
08/07/13Covidien to Host Investor Meeting on September 12, 2013
DUBLIN--(BUSINESS WIRE)--Aug. 7, 2013-- Covidien (NYSE: COV), a leading global provider of healthcare products, will host an investor meeting on Thursday, September 12, 2013, to update the investment community on the Company and its growth initiatives, strategic priorities and financial outlook. The event, held at Cipriani, 55 Wall Street, New York, NY, will begin at 10:00 a.m. ET and is expected to conclude by 5:00 p.m. The program... 
 Printer Friendly Version
08/06/13Medtronic Introduces the First and Only Neurostimulation Systems for Chronic Pain Designed for Full-Body MRI Safety*
Innovative Design Enhancements Provide Patients Unprecedented Access to Diagnostic Care MINNEAPOLIS - August 6, 2013 - With the first U.S. implants of its new RestoreSensor® SureScan® MRI neurostimulation systems, Medtronic, Inc. (NYSE: MDT) is introducing the first and only implantable neurostimulation (also known as spinal cord stimulation, or SCS) systems for use in the treatment of chronic, intractable back and/or limb pain that are approved by the U.S. Food and Drug Administration (FDA) fo... 
Download PDFPrinter Friendly Version
08/01/13Covidien Reports Third-Quarter Results
Net sales up 3% (up 5%, excluding foreign exchange rate movement); Medical Devices sales up 4% (up 6%, excluding foreign exchange rate movement) Third-quarter diluted GAAP earnings per share from continuing operations were $0.85; excluding specified items, adjusted diluted earnings per share from continuing operations were $0.91 DUBLIN--(BUSINESS WIRE)--Aug. 1, 2013-- Covidien plc (NYSE: COV) today repo... 
Download PDFPrinter Friendly Version
07/24/13Medtronic Announces 2013 "Global Heroes"
25 Distance Runners from Around the World Who Benefit from Medical Technology to Run Medtronic Twin Cities Marathon Events this Fall MINNEAPOLIS - July 24, 2013 - Twenty-five long-distance runners who benefit from medical technology have been named to the 2013 "Medtronic Global Heroes" team, and will run the Medtronic Twin Cities Marathon or TC 10 Mile on Sunday, October 6, 2013. This year's team includes runners from 12 different countries including Australia, China, Ireland, Isr... 
Download PDFPrinter Friendly Version
07/19/13HeartWare Schedules Second Quarter Conference Call And Webcast
FRAMINGHAM, Mass. and SYDNEY, July 19, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ:HTWR, ASX:HIN) has scheduled a conference call to discuss its financial results for the three months ended June 30, 2013, at 8:00 a.m. U.S. Eastern Daylight Time on Thursday, August 8, 2013. The Company plans to release the financial results prior to the conference call. The conference call with management will discuss the Company's financial results, highlights from the second quarter and busine... 
 Printer Friendly Version
07/17/13Covidien Declares Quarterly Cash Dividend
DUBLIN--(BUSINESS WIRE)--Jul. 17, 2013-- Covidien plc (NYSE: COV) today announced that its Board of Directors has declared a quarterly cash dividend of $0.26 per ordinary share. The dividend is payable on August 15, 2013, to shareholders of record as of the close of business on July 30, 2013. ABOUT COVIDIEN Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient o... 
 Printer Friendly Version
07/12/13Medtronic Issues Statement on Ruling in Germany
MINNEAPOLIS -- July 12, 2013 --Today a court in Mannheim Germany found that Medtronic's CoreValve® System infringes a patent owned by Edwards Lifesciences (the Spenser patent). Medtronic, Inc. (NYSE: MDT) respectfully disagrees with the court's decision and intends to appeal. The court's decision will limit options for physicians and their patients who need transcatheter aortic valve procedures, which Medtronic believes is contrary to sound health policy. In a separate European Patent Office p... 
Download PDFPrinter Friendly Version
07/11/13Medtronic Announces New Screw for Market-Leading CD HORIZON® SOLERA® Spinal System
MEMPHIS, Tenn. - July 11, 2013 - Medtronic, Inc. (NYSE:MDT) today announced the global market introduction of the CD HORIZON® SOLERA® Spinal System Sagittal Adjusting Screw (SAS) which may be used in the surgical correction of complex spinal pathologies.  The SAS features a fixed head made of cobalt chrome that contains a sliding saddle.  This engineering concept gives vertebral body control with accommodation of rod seating, allowing surgeons the ability to position the SAS in the natural kypho... 
Download PDFPrinter Friendly Version
07/01/13Covidien Completes Separation of Pharmaceuticals Business
DUBLIN--(BUSINESS WIRE)--Jul. 1, 2013-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced it has completed the separation of its Pharmaceuticals business, which is now held by Mallinckrodt plc, a new independent company. Mallinckrodt will begin “regular way” trading on the New York Stock Exchange today under the symbol "MNK." The distribution of Mallinckrodt ordinary shares occurred on June 28, ... 
 Printer Friendly Version
06/26/13Medtronic Issues Medical Device Notifications Regarding the SynchroMed® Implantable Infusion System
FDA Classifies Notifications               MINNEAPOLIS - June 26, 2013 - In June 2013, Medtronic, Inc. (NYSE: MDT) initiated four medical device notifications to customers worldwide about the SynchroMed® Implantable Infusion System. These notifications provide clinicians with information to help identify and manage issues that impact the safe and reliable delivery of therapy using the SynchroMed Implantable Infusion System. ... 
Download PDFPrinter Friendly Version
06/24/13Medtronic Begins Overnight Artificial Pancreas Study
Study Marks Critical Milestone Toward Commercialization of a Third-Generation Artificial Pancreas System for People with Diabetes  MINNEAPOLIS - June 24, 2013 - Medtronic, Inc. (NYSE:MDT) today announced the first patient enrollments in the U.S. Overnight Closed Loop Study, a key feasibility trial to begin the commercialization path for a third-generation, fully automated artificial pancreas system for people with diabetes. Under an investigational device exemption granted by the U.S. Food... 
Download PDFPrinter Friendly Version
06/24/13Covidien Wins Gold Medical Design Excellence Award for Sonicision™ Cordless Ultrasonic Dissection System
Covidien iDrive™ Ultra powered stapling system named MDEA Finalist MANSFIELD, Mass.--(BUSINESS WIRE)--Jun. 24, 2013-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that its Sonicision™ cordless ultrasonic dissection system won the 2013 Medical Design Excellence Award (MDEA), one of the medical technology industry’s highest honors. Covidien’s iDrive™ Ultra powered stapling system was also an MDEA finali... 
 Printer Friendly Version
06/22/13Medtronic Insulin Pump with Threshold Suspend Reported to Safely Reduce Nocturnal Hypoglycemia Without Increasing A1C
ASPIRE In-Home Study Published in New England Journal of Medicine and Presented at American Diabetes Association Annual Scientific Sessions CHICAGO - June 22, 2013 - Study results published today in the New England Journal of Medicine and to be presented at the American Diabetes Association (ADA) 73rd Scientific Sessions report that the Threshold Suspend feature of a sensor-augmented insulin pump from Medtronic, Inc. (NYSE: MDT) safely reduces nocturnal hypoglycemia without affecting glycated h... 
Download PDFPrinter Friendly Version
06/20/13Medtronic Announces Date for 2013 Annual Meeting
Shareholders Invited to Attend Annual Meeting on Aug. 22, 2013 MINNEAPOLIS - June 20, 2013 - The board of directors of Medtronic, Inc. (NYSE: MDT), today announced that the company's annual meeting of shareholders will be held at 10:30 a.m. CDT on Thursday, Aug. 22, 2013 at Medtronic's Mounds View campus, located at 8200 Coral Sea Street N.E., Mounds View, Minnesota.  Shareholders of record at the close of business on July 1, 2013, will be eligible to vote at the meeting. About MedtronicMedtro... 
 Printer Friendly Version
06/20/13Medtronic Increases Its Cash Dividend by 8 Percent; Approves Share Repurchase Plan
MINNEAPOLIS - June 20, 2013 - The board of directors of Medtronic, Inc. (NYSE: MDT) today approved an 8 percent increase in its cash dividend, raising the quarterly amount to $0.28 per share of the Company's common stock, which would result in an annual amount of $1.12 per share.  This dividend increase brings the Company's current dividend yield to 2.2 percent and expected fiscal year 2014 dividend payout ratio to approximately 30 percent.  Medtronic's dividend has nearly quadrupled over the pa... 
Download PDFPrinter Friendly Version
06/20/13CLOTS 3 Study Delivers Lifesaving Results Using Covidien’s Blood Clot Prevention Technology
Study Shows Sequential Compression Sleeves Reduce DVT Events in Immobile Stroke Patients MANSFIELD, Mass.--(BUSINESS WIRE)--Jun. 20, 2013-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that an independent study conducted by the University of Edinburgh has successfully demonstrated the effectiveness of Covidien’s Kendall SCD™ system with Vascular Refill Detection Technology on immobile stroke pa... 
 Printer Friendly Version
06/18/13Covidien plc to Report Third-Quarter Results on August 1, 2013
DUBLIN--(BUSINESS WIRE)--Jun. 18, 2013-- Covidien plc (NYSE: COV) will report third-quarter results on August 1, 2013, before trading begins. The Company will hold a conference call for investors at 8:30 a.m. ET. The call can be accessed in the following ways: At Covidien’s website: http://investor.covidien.com By telephone: For both “listen-only” participants and those participants who wish to take par... 
 Printer Friendly Version
06/17/13First-of-Its-Kind Independent Review of INFUSE® Bone Graft Coordinated by Yale University is Complete
INFUSE Bone Graft Remains Important Treatment Option MINNEAPOLIS - June 17, 2013 - Medtronic, Inc. [NYSE: MDT] acknowledged today the publication of the findings from Yale University's third-party, independent review of INFUSE® Bone Graft, a proprietary formulation of recombinant human bone morphogenetic protein-2 (rhBMP-2) that was approved by the U.S. Food and Drug Administration (FDA) in 2002 for use in anterior lumbar interbody spine fusion to stimulate natural bone growth. Since it was app... 
Download PDFPrinter Friendly Version
06/17/13HeartWare Receives Conditional Approval From FDA to Enroll Supplemental Patient Cohort in Destination Therapy Trial
- Amended protocol includes enhanced blood pressure monitoring to ensure optimal patient management - FRAMINGHAM, Mass., and SYDNEY, June 17, 2013 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that the U.S. Food and Drug Administration (FDA) has granted conditional approval to an IDE (Investigational D... 
 Printer Friendly Version
06/14/13Medtronic Unveils Baseline Data Of Extreme Risk Patients Enrolled In CoreValve® U.S. Pivotal Trial
Study Presents Comprehensive Dataset of Patient Characteristics Collected on Extreme Risk TAVR Patients VANCOUVER - June 14, 2013 - Medtronic, Inc. (NYSE: MDT) today presented baseline characteristics of patients enrolled in the Extreme Risk Study of the Medtronic CoreValve U.S. Pivotal Trial at the Transcatheter Valve Therapies (TVT) conference. The study was designed to evaluate the outcomes of patients unsuitable for conventional aortic valve surgery who underwent treatment with the CoreVal... 
Download PDFPrinter Friendly Version
06/13/13Covidien Announces Effectiveness of Mallinckrodt Form 10 Registration Statement
Covidien Expects to Complete Separation of Mallinckrodt on June 28, 2013 DUBLIN--(BUSINESS WIRE)--Jun. 13, 2013-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that the Securities and Exchange Commission (SEC) has declared effective the Registration Statement on Form 10 filed by Mallinckrodt plc in connection with the separation of the Pharmaceuticals business from Covidien. Covidien expects to complet... 
 Printer Friendly Version
06/13/13Medtronic CFO Gary Ellis to Speak at Wells Fargo Healthcare Conference
MINNEAPOLIS - June 13, 2013 - Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the Wells Fargo Securities 2013 Healthcare Conference on Tuesday, June 18, 2013, in Boston. Gary Ellis, senior vice president and chief financial officer of Medtronic, will make a presentation about Medtronic beginning at 8:15 a.m. EDT (7:15 a.m. CDT). A live audio webcast of the presentation will be available on June 18, 2013, by clicking on the In... 
Download PDFPrinter Friendly Version
06/13/13HeartWare Presentation at the Wells Fargo Securities 2013 Healthcare Conference to be Webcast
FRAMINGHAM, Mass. and SYDNEY, June 13, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Wells Fargo Securities Research and Economics 2013 Healthcare Conference at 9:25 a.m. EDT on Tuesday, June 18, 2013.  The conference is being held June 18-19 at th... 
 Printer Friendly Version
06/13/13Medtronic Announces CE Mark of Its ReDuX(TM) Plier Instrument, an Innovative Device to Perform Osteotomies in Spinal Deformity Surgeries
Novel Disruptive Instrument for Controlled and Progressive Restoration of the Sagittal Imbalance in Patient with Spinal Deformity NICE, France - June 13, 2013 - Medtronic, Inc. (NYSE:  MDT) announced today the CE Mark (Conformité Européenne) and the European launch of the ReDuX(TM) Plier, a new instrument specially designed for use during osteotomies.  With the launch of this first specially-designed surgical instrument in the spinal orthopaedic industry, physicians in the European community ma... 
Download PDFPrinter Friendly Version
06/05/13Medtronic to Present at Goldman Sachs Healthcare Conference
MINNEAPOLIS - June 5, 2013 - Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the 34th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 11, 2013, in Rancho Palos Verdes, CA. Omar Ishrak, chairman and chief executive officer, and Gary Ellis, senior vice president and chief financial officer, will make a presentation about Medtronic beginning at 3:20 p.m. PDT (5:20 p.m. CDT). A live audio webcast of the present... 
Download PDFPrinter Friendly Version
06/04/13HeartWare Presentation At The Goldman Sachs 34th Annual Global Healthcare Conference To Be Webcast
FRAMINGHAM, Mass. and SYDNEY, June 4, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Goldman Sachs 34th Annual Global Healthcare Conference at 8:00 a.m. PDT (11:00 am EDT) on Wednesday, June 12, 2013.  The conference is being held June 11-13 at the ... 
 Printer Friendly Version
06/04/13Medtronic Nets FDA Clearance and 'CE' Mark for New Peripheral Angioplasty Balloon
Pacific Plus PTA Catheter Allows for Treatment of Myriad Arteries, from Renal and Iliac to Femoral and Popliteal MINNEAPOLIS -- June 4, 2013 -- Expanding its extensive portfolio of lesion-specific solutions for the interventional treatment of peripheral artery disease, Medtronic, Inc. (NYSE: MDT) announced today that the Pacific  Plus percutaneous transluminal angioplasty (PTA) catheter has received both U.S. Food and Drug Administration (FDA) clearance and the CE (Conformité Européenne) Mark.... 
Download PDFPrinter Friendly Version
06/04/13Covidien and Mallinckrodt to Present at Goldman Sachs Conference
MANSFIELD, Mass.--(BUSINESS WIRE)--Jun. 4, 2013-- Covidien (NYSE: COV), a leading global provider of healthcare products, will present at the Goldman Sachs 34th Global Healthcare Conference in Rancho Palos Verdes, CA, on Wednesday, June 12, 2013. José E. Almeida, Chairman, President and Chief Executive Officer, will represent the Company in a session scheduled to begin at 12:20 p.m. ET. Mark Trudeau, President, Pharmaceuticals, wil... 
 Printer Friendly Version
06/03/13Medtronic Reaches Major Milestone in Clinical Program for 'IN.PACT Admiral' Drug-Eluting Balloon
Company Plans to Submit First Module of U.S. Approval Application for Novel Peripheral Angioplasty Device to FDA Over Summer MINNEAPOLIS -- June 3, 2013 -- Continuing to demonstrate its ongoing commitment to advancing interventional treatments of peripheral artery disease and the evidence to support their adoption, Medtronic, Inc. (NYSE: MDT) announced today that enough patients have been enrolled in its clinical studies of the IN.PACT Admiral drug-eluting balloon to support the company's U.S.... 
Download PDFPrinter Friendly Version
05/31/13Endurant AAA Stent Graft Delivers Durable Outcomes for Abdominal Aortic Aneurysm Repair
Three-Year Clinical Data Presented at Annual Meeting of Society for Vascular Surgery Reaffirms Physician Confidence in Market-Leading Endovascular Device SAN FRANCISCO -- May 31, 2013 -- The Endurant AAA stent graft system from Medtronic, Inc. (NYSE: MDT) continues to distinguish itself, with new data on the market-leading device for the endovascular repair of abdominal aortic aneurysms demonstrating durable clinical performance through three years of patient follow-up. Presented at the Society ... 
Download PDFPrinter Friendly Version
05/30/13Medtronic Garners First-Of-Its-Kind FDA Approval for 'AUI' Device with Endurant II AAA Stent Graft System
Global Market-Leader in Medical Technology for Endovascular Aortic RepairAlso Receives 510(k) Clearance for Sentrant Introducer Sheath MINNEAPOLIS -- May 30, 2013 -- Medtronic, Inc. (NYSE: MDT) is expanding its market-leading portfolio of products for endovascular aortic repair in the United States with two new medical devices: the company recently received approval from the U.S. Food and Drug Administration (FDA) for the Endurant II Aorto-Uni-Iliac (AUI) Stent Graft System and the FDA's 510(k)... 
Download PDFPrinter Friendly Version
05/28/13Covidien Nellcor™ Pulse Oximeters Receive FDA 510(k) Clearance with Labeling for Use in Newborn Screening for Critical Congenital Heart Disease
Labeling reconfirms device accuracy during patient motion; Nellcor pulse oximeters are the only oximeters on the market compliant with ISO 80601-2-61 BOULDER, Colo.--(BUSINESS WIRE)--May. 28, 2013-- Every year, nearly 7,200 infants are born in the United States with a Critical Congenital Heart Disease (CCHD).1 It is a condition that is often easily detectable and, when discovered, quite treatable. Far too frequently, however – in nearl... 
 Printer Friendly Version
05/24/13Medtronic CEO Omar Ishrak to Speak at Sanford Bernstein Strategic Decisions Conference
MINNEAPOLIS - May 24, 2013 - Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the Sanford Bernstein 29th Annual Strategic Decisions Conference on Friday, May 31, 2013 in New York. Omar Ishrak, chairman and chief executive officer of Medtronic will make a presentation about Medtronic beginning at 9:00 a.m. EDT (8:00 a.m. CDT). A live audio webcast of the presentation will be available on May 31, 2013, by clicking on the Invest... 
Download PDFPrinter Friendly Version
05/24/13Covidien Board of Directors Approves Separation of Pharmaceuticals Business and Declares Dividend of Mallinckrodt Ordinary Shares
DUBLIN--(BUSINESS WIRE)--May. 24, 2013-- Covidien plc (NYSE: COV), a leading global provider of healthcare products, today announced that its board of directors has approved the separation of the Pharmaceuticals business from the rest of Covidien. The separation will occur by means of the declaration of a dividend in specie of the Pharmaceuticals business, to be effected by the transfer of the Pharmaceuticals business from Covidien to Mallinckrodt... 
 Printer Friendly Version
05/23/13Covidien and Mallinckrodt to Present at Deutsche Bank Conference
MANSFIELD, Mass.--(BUSINESS WIRE)--May. 23, 2013-- Covidien (NYSE: COV), a leading global provider of healthcare products, will present at the Deutsche Bank 38th Annual Health Care Conference in Boston on Wednesday and Thursday, May 29 and 30, 2013. José E. Almeida, Chairman, President and Chief Executive Officer, will represent the Company in a session scheduled for May 30, 2013, at 12:00 p.m. ET. Mark Trudeau, President, P... 
 Printer Friendly Version
05/23/13Medtronic Completes Enrollment in Landmark U.S. Study of Symplicity(TM) Renal Denervation System for Treatment-Resistant Hypertension
Milestone Marks a Critical Step Forward in Bringing Renal Denervation to Patients in the U.S. MINNEAPOLIS - May 23, 2013 - Medtronic, Inc. (NYSE: MDT), today announced it has finished randomizing Symplicity HTN-3, the company's pivotal U.S. clinical trial of the Symplicity(TM) renal denervation system for treatment-resistant hypertension. Renal denervation is a minimally invasive, catheter-based procedure to reduce activity of the renal (kidney) nerves, which are part of the sympathetic nervous... 
Download PDFPrinter Friendly Version
05/23/13Medtronic CoreValve® System Gains First Approval for Transcatheter Valve-In-Valve Procedures
Replacing Degenerated Surgical Valves with CoreValve Results inSignificant Hemodynamic Improvements for Patients MINNEAPOLIS - May 23, 2013 - Medtronic, Inc. (NYSE: MDT) today announced it has received Conformité Européenne (CE) Mark for valve-in-valve (VIV) procedures using the CoreValve® and CoreValve® Evolut(TM) transcatheter aortic valve implantation (TAVI) systems in degenerated bioprosthetic surgical aortic valves. This is the first ever regulatory approval for VIV procedures, which prov... 
Download PDFPrinter Friendly Version
05/23/13Medtronic's In.Pact Falcon Drug-Eluting Balloon Yields Positive Outcomes in Small Coronary Arteries
Presented at EuroPCR, One-Year Data from BELLO Study Show Durability of Clinical Results Following Treatment of De Novo Lesions with Novel Angioplasty Device PARIS -- May 23, 2013 -- One-year data from an Italian multicenter randomized controlled trial of the IN.PACT Falcon drug-eluting balloon from Medtronic, Inc. (NYSE: MDT) demonstrate positive and durable clinical results with the novel angioplasty device in the treatment of stenotic de novo lesions in small coronary arteries, according to ... 
Download PDFPrinter Friendly Version
05/22/13Covidien Announces Clinical Trial Data Showing Endoscopic Ablation Therapy Eliminates Precancerous Esophageal Tissue and Significantly Reduces Disease Progression
Endoscopic ablation in patients with Barrett’s esophagus containing confirmed low-grade dysplasia reduces the relative risk for disease progression by 94% as compared to controls ORLANDO, Fla.--(BUSINESS WIRE)--May. 22, 2013-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that results from a prospective, multicenter, randomized, controlled clinical trial show that endoscopic ablation therapy using ... 
 Printer Friendly Version
05/22/13For Bifurcation Lesions in Coronary Arteries, Medtronic's Resolute Stent Delivers Strong Long-Term Results
(Thomson Reuters ONE via COMTEX) --Three Analyses Presented at EuroPCR Demonstrate Device's Durability in Addressing Common Clinical Challenge PARIS -- May 22, 2013 -- Addressing one of the most common clinical challenges in the treatment of complex coronary artery disease, three separate analyses on the program for EuroPCR this week show how strongly the Resolute drug-eluting stent from Medtronic, Inc. (NYSE: MDT) performs in coronary bifurcation lesions over the long term. Bifurcation le... 
Download PDFPrinter Friendly Version
05/21/13Medtronic Announces CE Mark and Launch for CapSureFix Novus(TM) 5076 MRI Lead
(Thomson Reuters ONE via COMTEX) --Proven Lead Expands Access to MRI for Patients with Slow Heartbeat TOLOCHENAZ - May 21, 2013 -- Medtronic today announced CE Mark (Conformite Europeenne) and launch of its CapSureFix Novus(TM)5076 Lead, which is now approved in the EU for use in an MRI environment when paired with a Medtronic MR-Conditional pacemaker. The lead has not been approved for that use in the U.S. The CapSureFix Novus 5076 Lead, previously approved for use with Medtronic's non MR-C... 
Download PDFPrinter Friendly Version
05/21/13Fourth Quarter Caps Solid Year for Medtronic
Q4 Revenue of $4.5 Billion Grew 5% at Constant Currency; 4% as Reported Q4 Non-GAAP Diluted EPS Growth of 11%; GAAP Diluted EPS Growth of 1% Q4 International Revenue Grew 7% at Constant Currency; 4% as Reported FY13 Revenue of $16.6 Billion Grew 5% at Constant Currency; 3% as Reported FY13 Free Cash Flow of $4.4 Billion; GAAP Cash Flow from Operations of $4.9 Billion Company Sets Initial FY14 Revenue Growth Outlook and EPS Guidance MINNEAPOLIS - May 21, 2013 - Medtronic, Inc. (NY... 
Download PDFPrinter Friendly Version
05/21/13Covidien’s Technology Platform to Diagnose Early Lung Cancer Part of New Guidelines of American College of Chest Physicians
Minimally invasive procedure aids early detection and diagnosis of lung cancer, potentially increasing long-term survival rates significantly MINNEAPOLIS--(BUSINESS WIRE)--May. 21, 2013-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that its superDimension Electromagnetic Navigation Bronchoscopy (ENB™) system, the first technology of its kind, is included in the new American College of C... 
 Printer Friendly Version
05/21/13Medtronic Finds TAVI with CoreValve® System Cost Effective for Treating Patients with Severe Aortic Stenosis
(Thomson Reuters ONE via COMTEX) --EuroPCR Presentation of "Real World" ADVANCE Study Confirms Economic Value of Novel Self-Expanding Valve in Patients Unable to Undergo Surgery PARIS -- May 21, 2013 -- Focused on offering devices that provide both clinical and economic value, Medtronic, Inc. (NYSE: MDT) today unveiled the results of a cost-effectiveness model comparing transcatheter aortic valve implantation (TAVI) with the CoreValve System to medical management. Presented at EuroPCR 2013, th... 
Download PDFPrinter Friendly Version
05/21/13Medtronic's Multi-Electrode, Simultaneously Firing Renal Denervation Catheter Shows Reduced Procedure Times While Demonstrating Significant Blood Pressure Reduction
(Thomson Reuters ONE via COMTEX) --Initial Results from Feasibility Study of the Symplicity Spyral(TM) Catheter Show Safety and Efficacy While More than Halving Mean Procedure Time MINNEAPOLIS and PARIS - MAY 21, 2013 - Medtronic, Inc. (NYSE: MDT) announced today preliminary results from the feasibility study of its Symplicity SpyralTM multi-electrode, 6 Fr renal denervation catheter, which showed safe, significant blood pressure reduction at one month in patients with treatment-resistant hype... 
Download PDFPrinter Friendly Version
05/21/13Medtronic CoreValve ADVANCE Study Demonstrates Low Rates of Mortality and Stroke and Sustained Valve Performance
(Thomson Reuters ONE via COMTEX) --EuroPCR Presentation of One-Year Data from Robust "Real World" Global Study Demonstrates One of the Lowest Mortality Rates among Similar TAVI Studies PARIS -- May 21, 2013 -- Committed to generating robust clinical data on its CoreValve System for transcatheter aortic valve implantation (TAVI), Medtronic, Inc. (NYSE: MDT) today unveiled for the first time the complete one-year data from the "real world" Medtronic CoreValve ADVANCE Study. Presented at EuroPCR ... 
Download PDFPrinter Friendly Version
05/21/13Medtronic Announces Data From Largest Real-World Patient Population Confirm Strong Safety Profile and Clinical Efficacy of Renal Denervation with the Symplicity(TM) System
(Thomson Reuters ONE via COMTEX) --First Look at Data from Global SYMPLICITY Registry Shows Renal Denervation with the Symplicity(TM) System Meets Performance Expectations in Real-World Setting MINNEAPOLIS and PARIS - MAY 21, 2013 - Medtronic, Inc. (NYSE: MDT), announced today the first results from the Global SYMPLICITY Registry, which reaffirmed the safety of the renal denervation procedure with the Symplicity(TM) renal denervation system in a real-world patient population. Among the 617 reg... 
Download PDFPrinter Friendly Version
05/20/13Medtronic to Honor Those Who Give Back After Receiving Life-Enhancing Medical Technology
(Thomson Reuters ONE via COMTEX) --(View the Bakken Invitation video here) Live On. Give On: Ten inspirational people will be awarded a $20,000 charitable donation and be honored at an awards celebration in Hawaii as part of the first annual Bakken Invitation MINNEAPOLIS - May 20, 2013- Medtronic, Inc. (NYSE: MDT) announced today that applications are being accepted for the inaugural Bakken Invitation, a global program designed to celebrate those who, with the help of medical technology, hav... 
Download PDFPrinter Friendly Version
05/20/13Covidien Receives FDA 510(k) Clearance for Nellcor™ Pulse Oximetry Motion Claims
Nellcor pulse oximeters only FDA 510(k)-cleared oximeters compliant with ISO 80601-2-61 BOULDER, Colo.--(BUSINESS WIRE)--May. 20, 2013-- Covidien, a leading global provider of healthcare products and recognized innovator in patient monitoring and respiratory care devices, today announced that its Nellcor™ pulse oximetry portfolio, which is used to measure arterial oxygen saturation, has received U.S. Food and Drug Administration (FDA) 5... 
 Printer Friendly Version
05/20/13Medtronic Receives 'CE' Mark for 'Export Advance' Aspiration Catheter
(Thomson Reuters ONE via COMTEX) --Backed by Robust Clinical Data on Broad Product Family, New Thrombus Removal System Offers Superior Deliverability MINNEAPOLIS -- May 20, 2013 -- Expanding its portfolio of medical technology for the interventional treatment of cardiovascular disease, Medtronic, Inc. (NYSE: MDT) announced today that the Export Advance aspiration catheter recently received the CE (Conformite Europeenne) mark and will soon be launched in Europe and other international markets... 
Download PDFPrinter Friendly Version
05/16/13HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast
FRAMINGHAM, Mass. and SYDNEY, May 16, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the 2013 UBS Global Healthcare Conference at 11:00 a.m. EDT on Monday, May 20, 2013.  The conference is being held May 20-22, 2013 at the Sheraton New York Hotel. A ... 
 Printer Friendly Version
05/14/13Medtronic to Announce Financial Results for Its Fourth Quarter and Fiscal Year 2013
(Thomson Reuters ONE via COMTEX) --MINNEAPOLIS - May 14, 2013 - Medtronic, Inc. (NYSE: MDT) announced today it will report financial results for the fourth quarter and fiscal year 2013 on Tuesday, May 21, 2013. A news release will be issued at approximately 6:15 a.m. Central Time and will be available at www.medtronic.com/newsroom The earnings news release will include summary financial information for Medtronic's fourth quarter and fiscal year, which ended April 26, 2013. Medtronic will host ... 
Download PDFPrinter Friendly Version
05/13/13Covidien Announces Pricing of $750 Million Senior Notes Offering
DUBLIN--(BUSINESS WIRE)--May. 13, 2013-- Covidien plc (NYSE: COV) today announced that its wholly-owned subsidiary, Covidien International Finance S.A. (CIFSA), priced an underwritten offering of $750 million aggregate principal amount of 2.950% senior notes due 2023. The offering is expected to close on May 16, 2013. These notes are fully and unconditionally guaranteed on a senior unsecured basis by Covidien plc and its subsidiary, Covidi... 
 Printer Friendly Version
05/13/13Covidien Announces Senior Notes Offering
DUBLIN--(BUSINESS WIRE)--May. 13, 2013-- Covidien plc (NYSE: COV) today announced that its wholly-owned subsidiary, Covidien International Finance S.A. (CIFSA), launched an underwritten offering of senior notes. These notes will be fully and unconditionally guaranteed on a senior unsecured basis by Covidien plc and its subsidiary, Covidien Ltd. CIFSA intends to use the proceeds from the offering to fund the repayment at maturity of all of its outs... 
 Printer Friendly Version
05/11/13Biventricular Pacing Reduces Symptoms and Improves Quality-of-Life in AV Block Patients with Heart Failure and Reduced Pumping Function
(Thomson Reuters ONE via COMTEX) --New Medtronic Data Show Additional Clinical Advantages in Pacing Both Ventricles Versus Conventional Right-Ventricular Pacing MINNEAPOLIS and DENVER - May 11, 2013 - Medtronic, Inc. (NYSE: MDT) today announced new data demonstrating that simultaneously pacing the lower chambers of the heart, or biventricular (BiV) pacing with a cardiac resynchronization therapy (CRT) device, significantly improves heart failure symptoms and quality of life in a subset of hear... 
Download PDFPrinter Friendly Version
05/10/13Data Show Medtronic-Exclusive LIA Software Detects Non-Medtronic Lead Issues at a Greater Rate Than Standard Impedance Monitoring
(Thomson Reuters ONE via COMTEX) --MINNEAPOLIS and DENVER - May 10, 2013 - Data presented today at Heart Rhythm 2013, the Heart Rhythm Society's 34th Annual Scientific Sessions, show that Medtronic, Inc. (NYSE:MDT) Lead Integrity Alert (LIA) software detected pace/sense lead issues in non-Medtronic leads at a greater rate than standard impedance monitoring alone (impedance monitoring measures the electrical continuity of a lead four times per day). The retrospective analysis, which focused on En... 
Download PDFPrinter Friendly Version
05/10/13New Research Demonstrates Success of Shock Avoidance in Medtronic Defibrillators
(Thomson Reuters ONE via COMTEX) --"Shock-Less" Late Breaking Clinical Trial: Providing Clinicians with ICD Programming Reports Improves Adherence to Evidence-Based Guidelines, Reduces All-Cause Shocks PainFree SST Trial: More Than 98 Percent of Patients with SmartShock(TM) Technology Are Free of Inappropriate Shock at One Year ADVANCE III Trial: Waiting to Deliver ICD Therapy Combined with ATP During Charging(TM) Reduces the Rate of Inappropriate Shocks by 45 Percent and Reduces Rate of Hos... 
Download PDFPrinter Friendly Version
05/10/13HeartWare Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference to be Webcast
FRAMINGHAM, Mass. and SYDNEY, May 10, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Bank of America Merrill Lynch 2013 Health Care Conference at 8:00 a.m. PDT (11:00 am EDT) on Thursday, May 16, 2013.  The conference is being held May 14-16, 2013 a... 
 Printer Friendly Version
05/08/13Covidien and Mallinckrodt to Present at Bank of America Merrill Lynch Conference
MANSFIELD, Mass.--(BUSINESS WIRE)--May. 8, 2013-- Covidien (NYSE: COV), a leading global provider of healthcare products, will present at the Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas, NV, on Wednesday, May 15, 2013. Bryan Hanson, Group President, Surgical Solutions, will represent the Company in a session scheduled at 1:40 p.m. ET. Mark Trudeau, President, Pharmaceuticals, will discuss Mallinckrodt, th... 
 Printer Friendly Version
05/06/13Medtronic Announces FDA Approval of New Portfolio of Next-Gen Cardiac Resynchronization Therapy Devices, Implantable Cardioverter-Defibrillators
     Newly designed Devices Result in Fewer Hospitalizations for Patients, Deliver Increased Longevity, and Improved Comfort MINNEAPOLIS - May 6, 2013 - Medtronic, Inc. (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval and U.S. launch of its newest cardiac devices: the Viva®portfolio of cardiac resynchronization therapy with defibrillation (CRT-D) devices, and the Evera® portfolio of implantable cardioverter-defibri... 
Download PDFPrinter Friendly Version
05/06/13Covidien Appoints Jacqueline Strayer Senior Vice President, Corporate Communications
DUBLIN--(BUSINESS WIRE)--May. 6, 2013-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced the appointment of Jacqueline Strayer as Senior Vice President, Corporate Communications, effective immediately. She will report to José E. Almeida, Chairman, President and CEO and be located in Mansfield, MA. In this role, Strayer will be responsible for leading Covidien's global communications strategies.... 
 Printer Friendly Version
05/03/13Covidien Announces First Full-Year Outlook for Mallinckrodt plc
DUBLIN--(BUSINESS WIRE)--May. 3, 2013-- Covidien (NYSE:COV) today announced 2013 full year guidance for Mallinckrodt plc as Mallinckrodt prepares to spin off from Covidien to become a separate, publicly traded company in mid-2013. Mallinckrodt’s fiscal year will end on September 27, 2013, with net sales growth expected to be in the range of 7% to 11% versus 2012, assuming foreign exchange rates at current levels. Net sales are expec... 
 Printer Friendly Version
05/03/13Covidien Announces 2013 Guidance and Provides Historical Financial Statements Adjusted for Discontinued Operations
Company will hold conference call on Monday, May 6 DUBLIN--(BUSINESS WIRE)--May. 3, 2013-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced revised 2013 guidance and released historical financial statements adjusted for the upcoming expected discontinued operations, reflecting the planned spin-off of its Pharmaceuticals business. These adjusted financial statements cover fiscal years 2010 to 2012 and the ... 
 Printer Friendly Version
05/02/13Medtronic Announces FDA Classification of Deep Brain Stimulation Lead Cap Communication
(Thomson Reuters ONE via COMTEX) --MINNEAPOLIS - May 2, 2013 - In keeping with its commitment to keep physicians informed about product performance and safety, Medtronic, Inc. (NYSE: MDT) issued an Urgent Medical Device Correction notification in February 2013 to provide physicians with information concerning the potential for deep brain stimulation (DBS) lead damage associated with the use of the lead cap provided in Medtronic DBS lead kits and dystonia therapy kits. The U.S. Food and Drug Admi... 
Download PDFPrinter Friendly Version
05/01/13Ten Local High School Graduates Named 2013 Medtronic Scholars
Medtronic has committed more than $1.6 million in local scholarships to 100 students. MINNEAPOLIS - May 1, 2013 - Medtronic today announced that 10 students have been selected as 2013 Medtronic Scholars. Each will receive a four-year scholarship totaling $16,000, as well as support services to assist them in their collegiate studies. Students represent nine Twin Cities' north suburban high schools, and one Minneapolis high school. The class of 2013 Medtronic Scholars will be honored at a May 6,... 
Download PDFPrinter Friendly Version
05/01/13Medtronic Partners with National Institute of Hospital Administration in China to Develop Diabetes Care Pathway
(Thomson Reuters ONE via COMTEX) --MINNEAPOLIS - May 1, 2013 - Medtronic, Inc. (NYSE: MDT) announced today it has entered into an innovative partnership with the National Institute of Hospital Administration, an important think tank under China's National Health and Family Planning Commission, to carry out a series of research projects focusing on building an integrated care pathway for patients with Type 1 diabetes. This effort is an example of a partnership focused on working with an important... 
Download PDFPrinter Friendly Version
04/29/13HeartWare International Reports $49.2 Million In First Quarter 2013 Revenue; 87% Increase From First Quarter Of 2012
- U.S. Revenues of $26.2 million, from $6.4 million in First Quarter of 2012; Reflecting First Complete Quarter of Commercialization in U.S. - - Conference call today at 5:00 p.m. U.S. E.T. - FRAMINGHAM, Mass. and SYDNEY, April 29, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced revenue of $49.2... 
 Printer Friendly Version
04/29/13Medtronic Introduces New MAST ALIGNED(SM) Procedure for Minimally Invasive Multi-Level Spinal Fusions
(Thomson Reuters ONE via COMTEX) --MEMPHIS, TENN. - April 29, 2013- Medtronic, Inc. (NYSE: MDT) the world leader in spinal technology announced today the global launch of the MAST ALIGNEDSM procedure. This comprehensive surgical solution includes technologies to access the spine, such as oblique lateral, as well as interbody, navigation, and biologics options. At the core of the MAST ALIGNEDSM procedure is the new CD HORIZON® LONGITUDE® II System, a multi-level percutaneous fixation system desig... 
Download PDFPrinter Friendly Version
04/29/13Medtronic Reports Initial Implants of Novel Stent Graft for Aortic Aneurysms Involving Branch Vessel
(Thomson Reuters ONE via COMTEX) --FDA's Early Feasibility Pilot Program for New Medical Devices Encourages Clinical Studies of Innovative Technology to Occur First in U.S. MINNEAPOLIS -- April 29, 2013 -- Vascular specialists at Carolinas HealthCare System in Charlotte, N.C., and the Cleveland Clinic in Ohio recently performed the initial implants of a novel stent graft system from Medtronic, Inc. (NYSE: MDT) as part of a U.S. Food and Drug Administration (FDA) initiative designed to encour... 
Download PDFPrinter Friendly Version
04/29/13Medtronic Expands Top Cervical-Upper Thoracic System
(Thomson Reuters ONE via COMTEX) --MEMPHIS, TENN. - April 29, 2013- Medtronic, Inc. (NYSE: MDT) the world leader in spinal technology announced today the U.S. launch of several new product line additions to the VERTEX SELECT® Reconstruction System. The announcement was made at the 81st American Association of Neurological Surgeons (AANS) Annual Scientific Meeting in New Orleans. This compliment to the VERTEX SELECT® Reconstruction System adds an additional selection of various size implants in... 
Download PDFPrinter Friendly Version
04/29/13Covidien Notification of Stolen Product - Single Lot of Non-Sterile Endo GIA ArticulatingTM 60 3.5mm Single Use Loading Unit
April 29, 2013 – Covidien is issuing this notification to inform the public of stolen, non-sterile Endo GIA ArticulatingTM 60-3.5 surgical stapler reloads, containing reference Code 030458 and lot number N3B0165LX. Covidien is working closely with the U.S. Food and Drug Administration (FDA) Office of Criminal Investigations (OCI), and other law enforcement organizations, to recover the stolen, non-sterile product. All units with the above-referenced lot number were stolen prior to sterili... 
 Printer Friendly Version
04/26/13Covidien Reports Second-Quarter Results
Net sales up 5% (up 7%, excluding foreign exchange rate movement); Medical Devices sales up 4% (up 6%, excluding foreign exchange rate movement) Second-quarter diluted GAAP earnings per share from continuing operations were $0.93; excluding specified items, adjusted diluted earnings per share from continuing operations were $1.12 DUBLIN--(BUSINESS WIRE)--Apr. 26, 2013-- Covidien plc (NYSE: COV) today re... 
Download PDFPrinter Friendly Version
04/24/13The New England Journal of Medicine: Medtronic Biventricular Pacing Delivers Better Patient Outcomes for Those with AV Block and Reduced Pumping Function
(Thomson Reuters ONE via COMTEX) --MINNEAPOLIS - April 24, 2013 - Biventricular (BiV) pacing with Medtronic, Inc. (NYSE: MDT) cardiac resynchronization therapy (CRT) devices may offer a significant clinical advantage and improved patient outcomes over conventional right ventricular (RV) pacing among patients with left ventricular (LV) systolic dysfunction and atrioventricular (AV) block who are indicated for a pacemaker. Results from the Medtronic-sponsored BLOCK HF trial show a 26 percent relat... 
Download PDFPrinter Friendly Version
04/24/13Medtronic Elects Scott C. Donnelly to the Board of Directors
(Thomson Reuters ONE via COMTEX) --MINNEAPOLIS - April 24, 2013 - Medtronic, Inc. (NYSE: MDT) today announced that its Board of Directors unanimously elected Scott C. Donnelly, chairman and CEO of Textron, Inc., a multi-industry company in the aircraft, defense, automobile, industrial and finance businesses worldwide, to the Board as an independent director, effective July 1, 2013. Mr. Donnelly has been president and CEO of Textron since 2009 and chairman of the Board of Directors since 2010, ... 
Download PDFPrinter Friendly Version
04/17/13Covidien Introduces New Surgical Access Devices at SAGES 2013
Company enters wound protector market with new SurgiSleeve™; Expands Versaport™ bladeless optical trocar portfolio BALTIMORE--(BUSINESS WIRE)--Apr. 17, 2013-- Covidien (NYSE: COV), a leading global provider of healthcare products, is launching two new surgical access devices at the annual meeting of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), which starts today. At the meeting, the Company also plans to conduct a ... 
 Printer Friendly Version
04/15/13American College of Cardiology Journal Publishes Outcomes of Diabetes Patients Treated with Medtronic's Resolute Stent
(Thomson Reuters ONE via COMTEX) --Implanted Medical Device for Coronary Artery Disease Performed As Well In Study Subjects With Diabetes Who Were Not Taking Insulin As In Those Without Diabetes MINNEAPOLIS -- April 15, 2013 -- The current issue of JACC: Cardiovascular Interventions, a peer-reviewed journal published by the American College of Cardiology, includes an article that describes how the Resolute Integrity drug-eluting stent from Medtronic, Inc. (NYSE: MDT) became the first and onl... 
Download PDFPrinter Friendly Version
04/15/13Covidien Launches New Shiley™ Neonatal and Pediatric Tracheostomy Tubes
Cuffless portfolio enhances tracheostomy care and safety for young patients BOULDER, Colo.--(BUSINESS WIRE)--Apr. 15, 2013-- Covidien (NYSE: COV), a leading global provider of healthcare products and recognized innovator in patient monitoring and respiratory care devices, today added a new product to its family of ShileyTM neonatal and pediatric tracheostomy tubes. The new cuffless product will help enhance patient care and safety withi... 
 Printer Friendly Version
04/15/13HeartWare Schedules First Quarter Conference Call And Webcast
FRAMINGHAM, Mass. and SYDNEY, April 15, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR, ASX:HIN) has scheduled a conference call to discuss its financial results for the three months ended March 31, 2013, at 5:00 p.m. U.S. Eastern Daylight Time on Monday, April 29, 2013. The Company plans to release the financial results prior to the conference call. The conference call with management will discuss the Company's financial results, highlights from the first quarter and busine... 
 Printer Friendly Version
04/11/13Medtronic Initiates U.S. Trial to Evaluate the Use of Subcutaneous Peripheral Nerve Stimulation for Chronic Back Pain
(Thomson Reuters ONE via COMTEX) --MINNEAPOLIS - April 11, 2013 - Medtronic, Inc. (NYSE: MDT) today announced the first patient enrollments in the SubQStim II pivotal clinical trial to pursue U.S. Food and Drug Administration (FDA) approval of peripheral nerve stimulation (PNS), also known as subcutaneous nerve stimulation (SQS), for the reduction of chronic, intractable post-surgical back pain. PNS involves an implant of electrical leads just under the skin of the lower back. These leads are ... 
Download PDFPrinter Friendly Version
04/11/13Covidien and VIDA Diagnostics Collaborate to Expand Minimally Invasive Treatment of Lung Disease
Combined use of market-leading diagnostic technologies opens door to treatment options MINNEAPOLIS--(BUSINESS WIRE)--Apr. 11, 2013-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced an agreement with VIDA Diagnostics, a pioneer in quantitative pulmonary imaging analysis software. Under the agreement, Covidien will distribute VIDA’s Apollo® pulmonary imaging software services. “We are commit... 
 Printer Friendly Version
04/09/13CardioGuide System Enables Real-Time Navigation of Left Ventricular Leads During Medtronic CRT Implants
System Available in U.S. and Canada MINNEAPOLIS - April 9, 2013 - Medtronic, Inc. (NYSE:MDT) today announced market release of the CardioGuide(TM) Implant System, a novel real-time navigation system for cardiac resynchronization therapy pacemakers and defibrillators (CRT-P and CRT-D), in the United States and Canada. The system helps physicians determine the most appropriate location for left-ventricular lead placement by generating 3-D images of the cardiac veins; enhanced software for the sys... 
Download PDFPrinter Friendly Version
04/09/13Medtronic's Endurant 'AAA' Stent Graft Shows Sustained Durability in Complex Patients
(Thomson Reuters ONE via COMTEX) --Analysis of ENGAGE Registry Found Similarly Strong Outcomes with Device for Endovascular Treatment of Abdominal Aortic Aneurysms in Short and Standard Neck Lengths MINNEAPOLIS -- April 9, 2013 -- Presented to endovascular specialists at the 35th Charing Cross International Symposium in London, a new analysis of clinical data on the Endurant AAA Stent Graft System from Medtronic, Inc. (NYSE: MDT) demonstrates the implanted medical device's consistent and compe... 
Download PDFPrinter Friendly Version
04/08/13Mallinckrodt International Finance S.A. Announces Private Offering of Senior Unsecured Notes
DUBLIN, Ireland - April 8, 2013 - Mallinckrodt International Finance S.A. (“MIFSA”), a wholly owned subsidiary of Covidien plc (NYSE: COV) which will become a wholly owned subsidiary of Mallinckrodt plc (“Mallinckrodt”) at the time of the completion of the separation of the Pharmaceuticals business of Covidien from its other businesses, announced today that, subject to market conditions, it plans to privately offer up to $900 million of senior unsecured notes (the &l... 
 Printer Friendly Version
04/08/13Mallinckrodt International Finance S.A. Announces Pricing of Senior Unsecured Notes Offering
DUBLIN, Ireland — April 8, 2013 — Mallinckrodt International Finance S.A. (“MIFSA”), a wholly owned subsidiary of Covidien plc (NYSE: COV) which will become a wholly owned subsidiary of Mallinckrodt plc (“Mallinckrodt”) at the time of the completion of the separation of the Pharmaceuticals business of Covidien from its other businesses, announced today that it has agreed to sell $300 million of 3.50% senior unsecured notes due 2018 (the “2018 Note... 
 Printer Friendly Version
04/04/13Medtronic Receives ‘CE’ Mark for Sentrant Introducer Sheath, Complementing Market-Leading Aortic Stent Grafts
Distinguishing Features of New Accessory for Endovascular Interventions Include Optimal Seal for Superior Hemostasis and Reinforced Coil for Proven Kink Resistance MINNEAPOLIS –– April 4, 2013 –– Complementing its market-leading portfolio of stent grafts for the endovascular repair of aortic aneurysms and related conditions, Medtronic, Inc. (NYSE: MDT) announced today that the Sentrant Introducer Sheath has received the CE (Conformité Européenne) mark and will soon be launched internationally. ... 
Download PDFPrinter Friendly Version
04/02/13Medtronic Announces FDA Clearance and First Uses of New Oxygenation System for Adult Cardiac Surgery
New System Designed for Patient Safety, Ease of Use During Open-Heart Procedures MINNEAPOLIS – April 2, 2013 – Medtronic, Inc. (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance and the first U.S. clinical uses of its new Affinity Fusion® oxygenation system. This system, which is designed to serve as a patient’s lungs by oxygenating and removing carbon dioxide from blood during various open-heart surgical procedures, incorporates numerous innovations for pat... 
Download PDFPrinter Friendly Version
03/29/13Covidien Awarded $176.5 Million Verdict in Patent Litigation against Ethicon Endo-Surgery
NEW HAVEN, Conn.--(BUSINESS WIRE)--Mar. 29, 2013-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that it has won a patent infringement suit against Ethicon Endo-Surgery, Inc., a Johnson & Johnson company, relating to Ethicon's Harmonic® line of ultrasonic surgical products. The federal court awarded Covidien a $176.5 million verdict upon ruling that several claims of Covidien’s patents were valid, ... 
 Printer Friendly Version
03/25/13Medtronic Applauds Ongoing Efforts of MN Delegation to Repeal Medical Device Tax
Medtronic recognized Senators Franken and Klobuchar, and Congressman Paulsen for recent efforts to introduce bipartisan-supported legislation to repeal the medical device excise tax. The tax went into effect January 1, 2013 adding a significant challenge to the medical device industry in its ability to continue to deliver innovative research and development and create jobs in an innovative sector of the Minnesota economy. We applaud continued efforts to address this challenge through a variety o... 
Download PDFPrinter Friendly Version
03/25/13Mallinckrodt Launches Additional Dosage Strengths of Generic CONCERTA® in U.S.
36 and 54 milligram dosage strengths of ADHD treatment now available ST. LOUIS--(BUSINESS WIRE)--Mar. 25, 2013-- Mallinckrodt, the Pharmaceuticals business of Covidien (NYSE: COV), today announced that it launched the 36 and 54 milligram (mg) dosage strengths of Methylphenidate HCl Extended-Release (ER) Tablets USP (CII), generic version of CONCERTA®. These two dosage strengths will be available in addition to the 27 mg dosage strength. The 27... 
 Printer Friendly Version
03/21/13Covidien Expands Share Repurchase Program and Declares Quarterly Cash Dividend
DUBLIN--(BUSINESS WIRE)--Mar. 21, 2013-- Covidien plc (NYSE: COV) today announced that its Board of Directors has authorized a new program to purchase up to $3 billion of the Company’s ordinary shares from time to time, based on market conditions. This program is in addition to the $2.0 billion share repurchase program announced in August 2011, which currently has approximately $425 million remaining. In the twelve months ending... 
 Printer Friendly Version
03/20/13Covidien Announces Results from 2013 Annual General Meeting
DUBLIN--(BUSINESS WIRE)--Mar. 20, 2013-- Covidien plc (NYSE: COV) announced the results from today’s Annual General Meeting. Eight proposals were on the meeting agenda: Election of Directors Appointment of Independent Auditors An advisory vote to approve the Company’s executive compensation Approval of the amended and restated Covidien Stock and Incentive Plan ... 
 Printer Friendly Version
03/19/13Medtronic Announces Public Offering of Senior Notes
MINNEAPOLIS –– March 19, 2013 –– Medtronic, Inc. (NYSE:MDT) today announced a registered offering of $1.0 billion of its 1.375% Senior Notes due 2018, $1.25 billion of its 2.750% Senior Notes due 2023 and $750 million of its 4.000% Senior Notes due 2043 (collectively, the “Notes”). The closing of the offering is expected to occur on March 26, 2013, subject to satisfaction of customary closing conditions. Medtronic intends to use the net proceeds for working capital and general corporate purposes... 
Download PDFPrinter Friendly Version
03/18/13HeartWare International, Inc. Announces Closing of Public Offering of Common Stock
FRAMINGHAM, Mass. and SYDNEY, March 18, 2013 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR, ASX: HIN) ("HeartWare") announced today the completion of a public offering of 1,725,000 shares of common stock, at a price per share of $86.45 pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission ("SEC") on December 9, 2010.  This amount includes 225,000 additional shares of common stock sold pursuant to the underwriters' exercise in fu... 
 Printer Friendly Version
03/15/13Covidien Announces Nominees to Board of Directors for Mallinckrodt Pharmaceutical Business
DUBLIN--(BUSINESS WIRE)--Mar. 15, 2013-- Covidien (NYSE:COV) today announced nominees to the future board of directors of Mallinckrodt plc as Mallinckrodt prepares to become a separate, independently traded company in mid-2013. It is expected that eight of the nine nominees will be determined to be independent directors, in accordance with the listing standards of the New York Stock Exchange. The service of all directors is expected to become ... 
 Printer Friendly Version
03/14/13Covidien plc to Report Second-Quarter Results on April 26, 2013
DUBLIN--(BUSINESS WIRE)--Mar. 14, 2013-- Covidien plc (NYSE: COV) will report second-quarter results on April 26, 2013, before trading begins. The Company will hold a conference call for investors at 8:30 a.m. ET. The call can be accessed in the following ways: At Covidien’s website: http://investor.covidien.com By telephone: For both “listen-only” participants and those participants who wish to tak... 
 Printer Friendly Version
03/13/13Covidien Launches Three New Hernia Care Products at American Hernia Society Annual Meeting
New mesh and fixation technology designed to offer improved treatment options for minimally invasive hernia procedures Company to host New Technology Designed To Improve Patient Outcomes symposium, highlighting recent hernia repair innovation on March 13 ORLANDO, Fla.--(BUSINESS WIRE)--Mar. 13, 2013-- Covidien (NYSE:COV), a leading global provider of healthcare products, is launching three new hernia care products that address ... 
 Printer Friendly Version
03/12/13HeartWare International, Inc. Announces Pricing of Public Offering of Common Stock
FRAMINGHAM, Mass. and SYDNEY, March 12, 2013 /PRNewswire/ --  HeartWare International, Inc. (Nasdaq: HTWR, ASX: HIN) ("HeartWare") announced today the pricing of a public offering of 1,500,000 shares of common stock at a price per share of $86.45 pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission ("SEC").  HeartWare also granted the underwriters an option to purchase up to an additional 225,000 shares to cover over-allotments, if any. ... 
 Printer Friendly Version
03/11/13With Medtronic Resolute Stent, Interrupting Dual Antiplatelet Therapy After One Month Showed No Increased Safety Risk in Robust Analysis
ACC.13 Presentation Features Unprecedented Data on Nearly 5,000 Patients, Including “All Comers,” from Global RESOLUTE Clinical Program SAN FRANCISCO –– March 11, 2013 –– Cardiologists at ACC.13 learned today that patients with coronary artery disease who received a Resolute drug-eluting stent from Medtronic, Inc. (NYSE: MDT) as participants in one of several clinical studies and interrupted or discontinued their dual antiplatelet therapy after one month of the implant procedure showed no in... 
Download PDFPrinter Friendly Version
03/11/13HeartWare International, Inc. Announces Public Offering of Common Stock
FRAMINGHAM, Mass. and SYDNEY, March 11, 2013 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR, ASX: HIN) ("HeartWare") announced today its intention to offer, subject to market and other conditions, 1,500,000 shares of common stock pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission ("SEC").  HeartWare also intends to grant the underwriters an option to purchase up to an additional 225,000 shares to cover over-allotments, if any.... 
 Printer Friendly Version
03/10/13New Data Reinforce Significant Blood Pressure Reduction Sustained to Two Years Using the Symplicity™ Renal Denervation System
24-Month Clinical Update from Symplicity HTN-2 Presented Today at the 62nd Annual Scientific Session of the American College of Cardiology MINNEAPOLIS and SAN FRANCISCO – March 10, 2013 – Medtronic, Inc. (NYSE: MDT) today announced 24-month data from Symplicity HTN-2, the first randomized clinical trial investigating renal denervation. Presented for the first time today at the 62nd Annual Scientific Session of the American College of Cardiology, the data show patients initially randomiz... 
Download PDFPrinter Friendly Version
03/08/13Medtronic CFO Gary Ellis to Speak at Barclays Global Healthcare Conference
MINNEAPOLIS – Mar 8, 2013 – Medtronic, Inc. (NYSE: MDT), the world’s leading medical technology company, today announced it will participate in the Barclays Global Healthcare Conference on Wednesday, March 13, 2013, in Miami. Gary Ellis, senior vice president and chief financial officer of Medtronic, will make a presentation about Medtronic beginning at 3:15 p.m. EDT (2:15 p.m. CDT). A live audio webcast of the presentation will be available on March 13, 2013, by clicking on the Investors lin... 
Download PDFPrinter Friendly Version
03/07/13Medtronic Submits IDE to FDA for U.S. Randomized Clinical Trial for Uncontrolled Hypertension Patients with Systolic Blood Pressure Between 140-160 mm Hg
IDE Submission for Symplicity HTN-4 Expands the Indicated Patient Population and Builds upon Medtronic’s Rigorous Global Clinical Trial Program for Hypertension Treatment MINNEAPOLIS – March 7, 2013 – Medtronic, Inc. (NYSE: MDT), announced today that the company has submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) to study the Symplicity™ renal denervation system for the treatment of uncontrolled hypertension in patients with systolic blood p... 
Download PDFPrinter Friendly Version
03/07/13Covidien to Present at Barclays Conference
MANSFIELD, Mass.--(BUSINESS WIRE)--Mar. 7, 2013-- Covidien (NYSE: COV), a leading global provider of healthcare products, will present at the 2013 Barclays Capital Global Healthcare Conference in Miami, Florida, on March 14, 2013. James C. Clemmer, President, Medical Supplies, will represent the Company in a presentation scheduled to begin at 10:15AM ET. A live audio webcast of the presentation can be accessed at Covidien’s Inve... 
 Printer Friendly Version
03/06/13Symplicity™ Renal Denervation System One of First Devices Accepted to Participate in Concurrent Review for Joint FDA Premarket Approval and Medicare National Coverage Determination
FDA-CMS Parallel Review Program Designed to Enable Efficient and Earlier Patient Access to Innovative Medical Advancements. MINNEAPOLIS – March 6, 2013 – Medtronic, Inc. (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) and the Centers for Medicare & Medicaid Services (CMS) have accepted the inclusion of the Symplicity™ renal denervation system for treatment-resistant hypertension in their parallel review program, which will allow CMS to begin consideration for national... 
Download PDFPrinter Friendly Version
03/06/13HeartWare Presentation at the Barclays Capital 2013 Global Healthcare Conference To Be Webcast
FRAMINGHAM, Mass., and SYDNEY, March 6, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Barclays Capital 2013 Global Healthcare Conference at 11:15 a.m. EDT on Tuesday, March 12, 2013.  The conference is being held March 12-14, 2013 at the Loews ... 
 Printer Friendly Version
03/05/13Medtronic Announces CE Mark and European Launch of Attain Performa® Portfolio of Quadripolar Leads
New Lead Portfolio Provides Options for Physicians to Deliver CRT Optimally and Efficiently MINNEAPOLIS – March 5, 2013 – Medtronic, Inc. (NYSE: MDT) today announced it has received CE (Conformité Européenne) Mark and will begin the European launch of the Attain Performa® portfolio of quadripolar leads. Paired with Medtronic Viva®/Brava® Quad cardiac resynchronization therapy defibrillators (CRT-D), Attain Performa left-heart leads provide additional options for physicians as they navigate d... 
Download PDFPrinter Friendly Version
03/04/13Medtronic Approved to Update Resolute Integrity Stent’s ‘CE’ Mark Labeling on Dual Antiplatelet Therapy
Interruption or Discontinuation After One Month Following Implant Procedure Posed ‘Low and No Increased Risk’ of Stent Thrombosis at One Year in Clinical Studies MINNEAPOLIS –– March 4, 2013 –– Of relevance to the clinical practice of interventional cardiology, Medtronic, Inc. (NYSE: MDT) announced today that it has received regulatory approval to update the CE (Conformité Européenne) mark labeling for the Resolute Integrity drug-eluting stent with new information on one month of dual antipl... 
Download PDFPrinter Friendly Version
03/04/13Medtronic Seeking Long-Distance Runners Who Benefit from Medical Technology
“Global Heroes” Will Receive Entry and Travel to the Medtronic Twin Cities Marathon or Medtronic TC 10 Mile in October MINNEAPOLIS – March 4, 2013 – Medtronic, Inc. (NYSE: MDT) announced today it is recruiting runners from around the world who benefit from medical technology to participate in the eighth annual Medtronic Global Heroes program.  Up to 25 runners will be selected to receive a paid entry for themselves and a guest to the Medtronic Twin Cities Marathon or the Medtronic TC 10 M... 
Download PDFPrinter Friendly Version
02/28/13Medtronic Announces CE Mark for Engager™ Transcatheter Valve
New Valve Provides Transapical Option for Physicians Treating Patients with Aortic Stenosis MINNEAPOLIS – February 28, 2013 – Medtronic, Inc. NYSE: MDT) today announced CE (Conformité Européenne) Mark of the Engager Transcatheter Aortic Valve Implantation (TAVI) System with transapical delivery catheter to treat patients with severe aortic stenosis who are at high or extreme risk for surgical aortic valve replacement (SAVR). The new valve demonstrated positive clinical outcomes in its Europ... 
Download PDFPrinter Friendly Version
02/28/13Medtronic EVP & President Chris O’Connell to Speak at Cowen Healthcare Conference
MINNEAPOLIS – Feb. 28, 2013 – Medtronic, Inc. (NYSE: MDT), the world’s leading medical technology company, today announced it will participate in the Cowen and Company 33rd Annual Healthcare Conference on Wednesday, March 6, 2013, in Boston. Chris O’Connell, executive vice president and president of Medtronic’s Restorative Therapy Group, will make a presentation about Medtronic beginning at 10:00 a.m. EST (9:00 a.m. CST). A live audio webcast of the presentation will be available on March 6, ... 
Download PDFPrinter Friendly Version
02/28/13HeartWare Presentation At Raymond James 34th Annual Institutional Investors Conference To Be Webcast
FRAMINGHAM, Mass. and SYDNEY, Feb. 28, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Raymond James 34th Annual Institutional Investors Conference at 1:05 p.m. Eastern Standard Time on Tuesday, March 5, 2013.  The conference is being ... 
 Printer Friendly Version
02/27/13Meta-Analysis Demonstrates Efficacy of Pillar Procedure for the Treatment of Snoring and Mild to Moderate Obstructive Sleep Apnea
Authors Reach Conclusions After a Meta-Analysis of 7 Clinical Studies for Snoring, and 7 Studies for OSA MINNEAPOLIS – Feb. 27, 2013 – In a meta-analysis of seven studies published in the January issue of Laryngoscope, Ji Ho Choi, M.D., Ph. D., and coauthors conclude that the Medtronic Pillar Procedure significantly reduced snoring loudness and mild-to-moderate obstructive sleep apnea (OSA). The Medtronic Pillar Procedure was cleared by the Food and Drug Administration (FDA) as a treatment... 
Download PDFPrinter Friendly Version
02/27/13HeartWare International Reports Fourth Quarter 2012 Revenue Of $32.7 Million; Full Year 2012 Revenue Of $110.9 Million
- Fourth Quarter 2012 U.S. Revenue of $13.4 Million; 60% Increase from Fourth Quarter 2011; Reflects FDA Approval and First Month of Commercialization in U.S. - - Globally more than 3,000 advanced heart failure patients have received the HeartWare® System - - Conference call today at 8:30 a.m. U.S. E.T. - FRAMINGHAM, Mass. and SYDNEY, Feb. 27, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory su... 
 Printer Friendly Version
02/26/13Medtronic Gains First FDA Approval to Conduct Early Feasibility Medical Device Study
Shared Commitment to Innovation Enables Early Study of Novel Native Outflow Tract Transcatheter Pulmonary Valve in Patients with Pulmonary Valve Failure MINNEAPOLIS – February 26, 2013 – Medtronic, Inc. (NYSE: MDT) today announced that it has received U.S. Food and Drug Administration (FDA) approval to conduct an early feasibility study using the Medtronic Native Outflow Tract Transcatheter Pulmonary Valve (TPV). This approval represents the first-ever FDA approval of an investigational device... 
Download PDFPrinter Friendly Version
02/25/13FDA Approves Longer Lengths of Medtronic’s Resolute Integrity Stent
New Sizes of Implantable Medical Device Target Long Coronary Lesions Common Among Diabetes Patients MINNEAPOLIS –– Feb. 25, 2013 –– Expanding the applicability of its marquee product for the interventional treatment of coronary artery disease in the United States, Medtronic, Inc. (NYSE: MDT) announced today that the U.S. Food and Drug Administration (FDA) has approved the 34mm and 38mm lengths of the Resolute Integrity drug-eluting stent in diameters of 3.0mm, 3.5mm and 4.0mm with an indicat... 
Download PDFPrinter Friendly Version
02/25/13Medtronic CFO Gary Ellis to Speak at Citi Global Healthcare Conference
MINNEAPOLIS – Feb. 25, 2013 – Medtronic, Inc. (NYSE: MDT), the world’s leading medical technology company, today announced it will participate in the Citi Global Healthcare Conference on Wednesday, February 27, 2013, in New York City. Gary Ellis, senior vice president and chief financial officer of Medtronic, will make a presentation about Medtronic beginning at 9:35a.m. EST (8:35a.m. CST). A live audio webcast of the presentation will be available on February 27, 2013, by clicking on the In... 
Download PDFPrinter Friendly Version
02/25/13Covidien to Present at Raymond James Conference
MANSFIELD, Mass.--(BUSINESS WIRE)--Feb. 25, 2013-- Covidien (NYSE: COV), a leading global provider of healthcare products, will present at the Raymond James 34th Annual Institutional Investors Conference in Orlando, Florida, on March 4, 2013. James C. Clemmer, President, Medical Supplies, will represent the Company in a presentation scheduled to begin at 8:40AM ET. A live audio webcast of the presentation can be accessed at Covidien’s ... 
 Printer Friendly Version
02/20/13Covidien Completes Patient Enrollment in Iliac Stent Clinical Study Series
VISIBILITY Iliac and DURABILITY Iliac Studies Evaluate the Safety and Effectiveness of Balloon Expandable and Self-Expanding Stents in Treating Iliac Artery Disease MANSFIELD, Mass.--(BUSINESS WIRE)--Feb. 20, 2013-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced the completion of patient enrollment in its iliac stent clinical study series. The series is composed of two prospective, multinational,... 
 Printer Friendly Version
02/19/13Medtronic Reports Third Quarter Earnings
Revenue of $4.0 Billion Grew 4% on a Constant Currency Basis; 3% as Reported International Revenue Grew 7% on a Constant Currency Basis; 5% as Reported Emerging Market Revenue Grew 21% on a Constant Currency Basis; 20% as Reported Non-GAAP Diluted EPS Growth of 11%; GAAP Diluted EPS Growth of 10% Free Cash Flow of $1.4 Billion; GAAP Cash Flow from Operations of $1.5 Billion MINNEAPOLIS – February 19, 2013 – Medtronic, Inc. (NYSE: MDT) today announced financial results for its third quar... 
Download PDFPrinter Friendly Version
02/19/13Covidien to Present at Upcoming Investor Conferences
MANSFIELD, Mass.--(BUSINESS WIRE)--Feb. 19, 2013-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that Charles J. Dockendorff, Executive Vice President and Chief Financial Officer, will represent the Company at two upcoming conferences: Citi 2013 Global Health Care Conference February 26, 2013 – New York, NY 3:00PM ET RBC Capital Markets Healthcare Conference February 27, 2013 ... 
 Printer Friendly Version
02/19/13HeartWare Schedules Fourth Quarter Conference Call and Webcast
FRAMINGHAM, Mass. and SYDNEY, Feb. 19, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR, ASX:HIN) has scheduled a conference call to discuss its financial results for the three months ended December 31, 2012, at 8:30 a.m. U.S. Eastern Standard Time on Wednesday, February 27, 2013. The Company plans to release the financial results prior to the conference call. The conference call with management will discuss the Company's financial results, highlights from the fourth quart... 
 Printer Friendly Version
02/14/13New Research Shows Significant Benefits of Medtronic Deep Brain Stimulation Earlier in Progression of Parkinson's Disease
EARLYSTIM study results published in The New England Journal of Medicine show remarkable improvements in patient quality of life and motor disability TOLOCHENAZ, SWITZERLAND – Feb. 14, 2013 – Results from a clinical study published today in The New England Journal of Medicine show that use of Medtronic (NYSE: MDT) deep brain stimulation (DBS) therapy provides superior benefits for patients with early motor complications from Parkinson’s disease when compared with best medical therapy only.1 ... 
Download PDFPrinter Friendly Version
02/14/13Medtronic Announces Cash Dividend for Fourth Quarter of Fiscal Year 2013
MINNEAPOLIS – February 14, 2013 – The board of directors of Medtronic, Inc. (NYSE:MDT) today approved a cash dividend of $0.26 per share of the Company’s common stock. The dividend is payable on April 26, 2013, to shareholders of record at the close of business on April 5, 2013. About Medtronic Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health, and extending life for millions of people around the ... 
Download PDFPrinter Friendly Version
02/13/13AIRvance™ Bone Screw System Gains Additional FDA Clearance
The AIRvance™ Bone Screw System Is Now Suitable for the Performance of a Hyoid Suspension Procedure, Which Can Be Used in Combination with Other Procedures for the Treatment of Obstructive Sleep Apnea MINNEAPOLIS – Feb. 13, 2013 – Medtronic announced today that it has received Food and Drug Administration (FDA) clearance for its AIRvance™ Bone Screw System that allows surgeons to perform a hyoid suspension procedure independently or in combination with other procedures for the treatment of o... 
Download PDFPrinter Friendly Version
02/13/13Medtronic Announces FDA Approval and Launch of Its Advisa MRI Pacemaker System
Second-generation MR-Conditional Pacemaker Combines Advanced Pacing Technology with MRI Access MINNEAPOLIS – February 13, 2013 – Showcasing its leadership position in pacing technologies, Medtronic, Inc. (NYSE: MDT), today announced the U.S. Food and Drug Administration (FDA) approval and U.S. launch of its Advisa DR MRI™ SureScan®  pacing system. The Advisa MRI system is Medtronic’s second-generation MR-Conditional pacemaker and is the first system to combine the most advanced pacing t... 
Download PDFPrinter Friendly Version
02/11/13Medtronic to Announce Financial Results for Its Third Quarter of Fiscal Year 2013
MINNEAPOLIS – Feb. 11, 2013 – Medtronic, Inc. (NYSE: MDT) announced today it will report financial results for the third quarter of its fiscal year 2013 on Tuesday, February 19, 2013. A news release will be issued at approximately 6:15 a.m. Central Time and will be available at www.medtronic.com/newsroom. The earnings news release will include summary financial information for Medtronic’s third quarter, which ended January 25, 2013. Medtronic will host a webcast at 7 a.m. Central Time to discu... 
Download PDFPrinter Friendly Version
02/08/13HeartWare Presentation at Leerink Swann Global Healthcare Conference to be Webcast
FRAMINGHAM, Mass. and SYDNEY, Feb. 8, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Leerink Swann Global Healthcare Conference at 8:30 a.m. Eastern Standard Time on Wednesday, February 13, 2013.  The conference is being held February 13-14 at t... 
 Printer Friendly Version
02/07/13Two-Year Clinical Study Supports Safety and Efficacy of Covidien Solitaire™ FR Revascularization Device
STAR Study Reviews Device Use in Blood Clot Removal Treatment for Patients Experiencing Acute Ischemic Stroke MANSFIELD, Mass.--(BUSINESS WIRE)--Feb. 7, 2013-- Covidien (NYSE:COV), a leading global provider of healthcare products, today released the results of the Solitaire™ FR Thrombectomy for Acute Revascularization (STAR) study. The two-year study evaluated the safety and efficacy of the Solitaire FR revascularization device ... 
 Printer Friendly Version
02/05/13Minnesota Timberwolves Star Ricky Rubio Teams Up with Medtronic Foundation to Save Young Lives from Sudden Cardiac Arrest
Rubio Helps Web Visitors Save a “Virtual” Life at HeartRescueNow.com MINNEAPOLIS, February 5, 2013 –Minnesota Timberwolves basketball star Ricky Rubio joins the Medtronic Foundation this February in saving young lives worldwide from sudden cardiac arrest (SCA). Through the Foundation’s HeartRescue Project, Rubio will lend a “virtual” hand in teaching the public how to respond quickly to an SCA emergency. Sudden Cardiac Arrest is the leading cause of death in young athletes—every three days... 
Download PDFPrinter Friendly Version
02/05/13Covidien Announces Continued Relationship with NYSE Euronext
Spin-off Mallinckrodt plc Will Apply for NYSE Listing DUBLIN--(BUSINESS WIRE)--Feb. 5, 2013-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that Mallinckrodt plc intends to apply to list its ordinary shares on the New York Stock Exchange (NYSE) to trade under the symbol MNK. As previously announced, Covidien plans to spin off its Pharmaceuticals business into Mallinckrodt, a stan... 
 Printer Friendly Version
02/04/13Medtronic Announces CE Mark of Evera® Portfolio of Implantable Cardioverter-Defibrillators
Next-Generation ICDs Offer Patients Proven Treatment Performance, Increased Longevity, Improved Comfort MINNEAPOLIS – February 4, 2013 – Medtronic today announced CE (Conformité Européenne) Mark of the Evera® portfolio of implantable cardioverter-defibrillators (ICD). With increased longevity and the most advanced shock reduction technology available, the new family of ICDs is the first to feature the PhysioCurve® design, a contoured shape with thin, smooth edges that better fits inside the ... 
Download PDFPrinter Friendly Version
02/01/13Covidien Announces Filing of Form 10 Registration Statement in Connection with Planned Spin-Off of Pharmaceuticals Business
DUBLIN--(BUSINESS WIRE)--Feb. 1, 2013-- Covidien plc (NYSE: COV) today announced the initial filing by Mallinckrodt plc of a Form 10 Registration Statement with the U.S. Securities and Exchange Commission (SEC) in connection with Covidien’s previously announced plan to spin off its Pharmaceuticals business. "The filing of the Form 10 Registration Statement is an important milestone in our ongoing separation process," said José E. Almei... 
 Printer Friendly Version
01/30/13Medtronic Completes Strategic Investment in LifeTech Scientific Corporation
Strategic Alliance to Leverage Best of Both Companies to Reach Cardiovascular Patients in China and Other Emerging Markets MINNEAPOLIS and Shenzhen – January 30, 2013 – Medtronic, Inc. (NYSE:MDT) and LifeTech Scientific Corporation (8122:HK) today announced the closing of a transaction creating a strategic alliance that brings together the resources and technologies of the world’s largest medical device company with the local market expertise, brand recognition and growth potential of a reco... 
Download PDFPrinter Friendly Version
01/30/13Medtronic Introduces the First and Only Neurostimulation Systems with CE Mark Approval for Full-Body MRI Scans
TOLOCHENAZ AND MINNEAPOLIS – January 30, 2013 – Medtronic, Inc. (NYSE: MDT) today introduced in Europe the first and only implantable neurostimulation systems indicated for use in the treatment of chronic back and/or leg pain that are designed for full-body Magnetic Resonance Imaging (MRI) scans under specific conditions. The first new system implants have been performed by Dr. JP Van Buyten and Dr. Iris Smet in Belgium; Dr. Rasche and Professor Tronnier in Germany; Dr. J. De Andres in Spain; D... 
Download PDFPrinter Friendly Version
01/28/13Medtronic Initiates Landmark Study of Neurostimulation Therapy for Failed Back Surgery Syndrome
First Patients Treated in Global Clinical Trial Evaluating Impact of Therapy on Predominant Low Back Pain MINNEAPOLIS – January 28, 2013 – Medtronic, Inc. (NYSE: MDT) today announced the start of PROMISE, a Prospective, Randomized Study of Multicolumn Implantable Lead Stimulation for Predominant Low Back Pain. This is the first-ever, large-scale study comparing the effectiveness of Medtronic neurostimulation therapy with Specify® 5-6-5 multicolumn surgical leads plus optimal medical manageme... 
Download PDFPrinter Friendly Version
01/25/13Covidien Reports First-Quarter Results
View PDF Net sales up 5%; Medical Devices sales up 8% First-quarter diluted GAAP earnings per share were $1.03; excluding specified items, adjusted diluted earnings per share were $1.10 Increasing fiscal 2013 net sales guidance in all segments DUBLIN--(BUSINESS WIRE)--Jan. 25, 2013-- Covidien plc (NYSE: COV) today reported results for the first quarter of fiscal 2013 (October - December 2012). First-quarter net sales of $3.06 billion were 5% above the $2.90 billion reported in the com... 
 Printer Friendly Version
01/24/13Medtronic Launches Lower-Extremity Indication for Complete ‘SE’ Vascular Stent Internationally
Self-Expanding Peripheral Device Gets CE Mark for Superficial Femoral and Proximal Popliteal Arteries MINNEAPOLIS –– Jan. 24, 2013 –– Expanding its role in the treatment of peripheral artery disease, Medtronic, Inc. (NYSE: MDT) today announced the CE (Conformité Européene) mark and international launch of its Complete SE (self-expanding) vascular stent for use in the lower extremities –– specifically, the superficial femoral arteries (SFA) and proximal popliteal arteries (PPA), which supply ... 
Download PDFPrinter Friendly Version
01/23/13Medtronic Drug-Eluting Balloon Study Completes Enrollment
Milestone in IN.PACT SFA II Brings FDA Submission for Promising Interventional Treatment of Peripheral Artery Disease One Step Closer in U.S. MINNEAPOLIS –– Jan. 23, 2013 –– Medtronic, Inc. (NYSE: MDT), today announced completion of enrollment in IN.PACT SFA II, the U.S. arm of its clinical study for the IN.PACT Admiral drug-eluting balloon as a treatment for peripheral artery disease in the superficial femoral and proximal popliteal arteries (SFA and PPA).  IN.PACT SFA II is a pro... 
Download PDFPrinter Friendly Version
01/23/13Covidien Receives CE Mark Approval for EverFlex™ Self-expanding Peripheral Stent with Entrust™ Delivery System
One-Handed Stent Delivery System Offers Controlled Delivery, Greater Accuracy and Ease of Use LEIPZIG, Germany - January 23, 2013 - Covidien, a leading global provider of healthcare products, today announced CE Mark approval for its EverFlex™ Self-expanding Peripheral Stent with Entrust™ Delivery System. The advanced stent delivery system, specifically engineered for optimal control, is designed to allow physicians to consistently place stents in the desired location with accuracy and ease.... 
 Printer Friendly Version
01/21/13Mallinckrodt Announces Approval of New Gablofen® Prefilled Syringe
Gablofen® (baclofen injection) in prefilled syringes helps simplify ITB refills HAZELWOOD, Mo.--(BUSINESS WIRE)--Jan. 21, 2013-- Mallinckrodt, the Pharmaceuticals business of Covidien (NYSE: COV), today announced the U.S. Food and Drug Administration (FDA) approval of Gablofen® (baclofen injection) in prefilled syringes. The Gablofen prefilled syringe was created to reduce preparation steps, helping to simplify the pump refill process for ... 
 Printer Friendly Version
01/17/13Living Heart Foundation Launches HOPE Program for Former NFL Players
Comprehensive study and educational program promotes healthy lifestyles and weight-management for retired professional football players PHILADELPHIA--(BUSINESS WIRE)--Jan. 17, 2013-- The Living Heart Foundation, with support from the National Football League Players Association and Covidien (NYSE: COV), today announced the launch of the HOPE (Heart, Obesity, Prevention & Education) Program for former National Football League (NFL... 
 Printer Friendly Version
01/16/13New Clinical Trial Will Use Continuous Cardiac Monitoring to Evaluate Atrial Fibrillation in High-Risk Patients
Medtronic Announces First Patient Implant in REVEAL AF Clinical Trial MINNEAPOLIS – January 16, 2013 – Medtronic, Inc. (NYSE: MDT) today announced the first patient implant for the REVEAL AF (Incidence of AF in High Risk Patients) Clinical Trial, which through continuous cardiac monitoring will evaluate the incidence of atrial fibrillation among patients suspected to be at a high-risk for the disease, and will identify key patient predictors for detection of AF. Using the Reveal® Insertabl... 
Download PDFPrinter Friendly Version
01/16/13Covidien Announces Launch of Therapeutic Device for Treatment of Resistant Hypertension
The OneShot™ Renal Denervation Device Offers a Solution for Physicians treating Patients with High Blood Pressure who Fail Drug Therapy MANSFIELD, Mass.--(BUSINESS WIRE)--Jan. 16, 2013-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced the commercial launch of the OneShot™ Renal Denervation System, an over the wire balloon-based irrigated catheter technology for the treatment of high blood pressure... 
 Printer Friendly Version
01/15/13Medtronic Announces Launch of FlexCath Advance™ Steerable Sheath, Enhancing the Arctic Front Advance™ Cryoballoon System
Second-Generation Sheath May Facilitate Easier Access to the Inferior Veins When Treating Paroxysmal Atrial Fibrillation MINNEAPOLIS – Jan. 15, 2013 – Medtronic, Inc. (NYSE: MDT) today announced Food and Drug Administration (FDA) clearance and U.S. launch of the FlexCath Advance™ Steerable Sheath, a new enhancement to the Arctic Front Advance™ Cryoballoon System. This second-generation sheath has an increased degree of deflection and response, providing greater ease compared to the previous ge... 
Download PDFPrinter Friendly Version
01/15/13Covidien Completes Enrollment in the DEFINITIVE AR Study
New Clinical Study Addresses Restenosis Prevention in Patients with Peripheral Artery Disease MANSFIELD, Mass.--(BUSINESS WIRE)--Jan. 15, 2013-- Covidien (NYSE:COV), a leading global provider of healthcare products, today announced the completion of enrollment in its DEFINITIVE AR (Anti-Restenosis) study. As the third study in the DEFINITIVE trial series, this randomized pilot is designed to address the challenge of preventing r... 
 Printer Friendly Version
01/14/13Covidien Opens Patient Enrollment for SWIFT PRIME Acute Ischemic Stroke Study
New Clinical Trial Represents One of the Largest Global Studies to Examine the Effectiveness of Advanced Mechanical Treatment in Stroke Care MANSFIELD, Mass.--(BUSINESS WIRE)--Jan. 14, 2013-- Covidien (NYSE:COV), a leading global provider of healthcare products, today announced the launch of a new study, SWIFT PRIME, which enrolled its first patient at the University at Buffalo. The new multi-center, randomized controlled trial will be... 
 Printer Friendly Version
01/10/13Covidien Completes Acquisition of CV Ingenuity
DUBLIN--(BUSINESS WIRE)--Jan. 10, 2013-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that it has completed the previously announced acquisition of CV Ingenuity. Financial terms of the transaction were not disclosed. CV Ingenuity’s core technology, still in the investigational phase, is a Drug Coated Balloon (DCB) platform with a novel, proprietary, tunable, rapid-release system. ... 
 Printer Friendly Version
01/10/13New Clinical Trial First to Evaluate Effectiveness of CRT-P in Symptomatic Heart Failure Patients with Mild-to-Moderate Structural Heart Disease
Medtronic-Sponsored Study Aims to Support Worldwide Indication Expansion for CRT-P in a Significantly Underserved Heart Failure Patient Population MINNEAPOLIS – Jan. 10, 2013 – Medtronic, Inc. (NYSE: MDT) today announced the first patient enrollment in MIRACLE EF, a global clinical trial that will evaluate the effectiveness of cardiac resynchronization therapy-pacemakers (CRT-Ps) in delaying the progression of heart failure in symptomatic patients with mildly reduced heart pumping function. ... 
Download PDFPrinter Friendly Version
01/07/13Medtronic Updates Fiscal 2013 EPS Guidance
MINNEAPOLIS – January 7, 2013 – In a presentation to investors, Medtronic, Inc. (NYSE:MDT) today updated diluted earnings per share (EPS) guidance for fiscal year 2013. The Company tightened its fiscal 2013 diluted EPS guidance range to $3.66 to $3.70 from the previously stated range of $3.62 to $3.70. The new range implies annual EPS growth of 6 to 7%. Management indicated that the Company’s updated fiscal 2013 EPS guidance is based on the positive financial impact from the recent renewal of... 
Download PDFPrinter Friendly Version
01/07/13HeartWare International Announces Preliminary Fourth Quarter 2012 Revenues
FRAMINGHAM, Mass. and SYDNEY, Jan. 7, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that it expects total revenues for the fourth quarter of 2012 will be approximately $32 million, bringing expected full-year 2012 revenues to approximately $110 million. "These results reflect positive initial... 
 Printer Friendly Version
01/07/13Covidien’s Tri-Staple™ Technology Platform Reaches $1 Billion Sales Milestone
Innovative and expanding surgical stapling portfolio offers outstanding clinical performance in wider range of laparoscopic surgical procedures MANSFIELD, Mass.--(BUSINESS WIRE)--Jan. 7, 2013-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that the Company’s Tri-Staple™ technology platform has achieved more than $1 Billion in product sales since launching in mid-2010. The ... 
 Printer Friendly Version
01/03/13HeartWare Presentation At The 31st Annual J.P. Morgan Healthcare Conference To Be Webcast
FRAMINGHAM, Mass. and SYDNEY, Australia, Jan. 3, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the 31st Annual J.P. Morgan Healthcare Conference at 10:30 a.m. Pacific Standard Time (1:30 p.m. EST) on Monday, January 7.  The conference is being held... 
 Printer Friendly Version
X